0001213900-20-012278.txt : 20200514 0001213900-20-012278.hdr.sgml : 20200514 20200514162022 ACCESSION NUMBER: 0001213900-20-012278 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200514 DATE AS OF CHANGE: 20200514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROONE MEDICAL TECHNOLOGIES Corp CENTRAL INDEX KEY: 0001500198 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 270863354 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54716 FILM NUMBER: 20878078 BUSINESS ADDRESS: STREET 1: 7599 ANAGRAM DR CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 BUSINESS PHONE: (952) 426-1383 MAIL ADDRESS: STREET 1: 7599 ANAGRAM DR CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 FORMER COMPANY: FORMER CONFORMED NAME: Original Source Entertainment, Inc. DATE OF NAME CHANGE: 20100830 10-Q 1 f10q0320_neuroonemed.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the Quarterly Period Ended March 31, 2020

-OR-

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transaction period from _________ to_________

Commission File Number: 000-54716

NeuroOne Medical Technologies Corporation

(Exact name of Registrant as specified in its charter)

Delaware		27-0863354
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

7599 Anagram Drive Eden Prairie, MN		55344
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 952-426-1383

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Non-accelerated filer	☒
Accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock as of May 8, 2020 was 16,154,122.

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

FORM 10-Q

INDEX

		Page
	PART 1 – FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Condensed Balance Sheets as of March 31, 2020 (unaudited) and September 30, 2019	1
	Condensed Statements of Operations for the three and six months ended March 31, 2020 and 2019 (unaudited)	2
	Condensed Statements of Changes in Stockholders’ Deficit for the three and six months ended March 31, 2020 and 2019 (unaudited)	3
	Condensed Statements of Cash Flows for the six months ended March 31, 2020 and 2019 (unaudited)	4
	Notes to Condensed Financial Statements (unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4.	Controls and Procedures	33

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3.	Defaults Upon Senior Securities	36
Item 4.	Mine Safety Disclosures	36
Item 5.	Other Information	36
Item 6.	Exhibits	37

SIGNATURES		38

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

NeuroOne Medical Technologies Corporation

Condensed Balance Sheets

	As of
	March 31, 2020			September 30, 2019
	(unaudited)
Assets
Current assets:
Cash	$	747,244		$	260,749
Prepaid and other assets		81,305			41,002
Total current assets		828,549			301,751
Right-of-use asset		308,055			—
Intangible assets, net		167,680			178,838
Property and equipment, net		84,943			52,026
Total assets	$	1,389,227		$	532,615

Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	1,077,225		$	1,152,472
Accrued expenses		291,874			617,721
Convertible promissory notes (Note 7)		4,921,076			—
Total current liabilities		6,290,175			1,770,193
Lease liability		284,235			—
Total liabilities		6,574,410			1,770,193

Commitments and contingencies (Note 4)

Stockholders’ deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2020 and September 30, 2019; no shares issued or outstanding as of March 31, 2020 and September 30, 2019.		—			—
Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and September 30, 2019; 14,022,423 and 13,493,705 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively.		14,023			13,494
Additional paid–in capital		18,022,373			15,987,799
Accumulated deficit		(23,221,579	)		(17,238,871	)
Total stockholders’ deficit		(5,185,183	)		(1,237,578	)
Total liabilities and stockholders’ deficit	$	1,389,227		$	532,615

See accompanying notes to condensed financial statements

NeuroOne Medical Technologies Corporation

Condensed Statements of Operations

(unaudited)

	For the Three Months Ended						For the Six Months Ended
	March 31,						March 31,
	2020			2019			2020			2019
Operating expenses:
General and administrative	$	1,035,256		$	1,084,789		$	2,347,422		$	1,951,468
Research and development		342,102			436,311			843,921			645,479
Total operating expenses		1,377,358			1,521,100			3,191,343			2,596,947
Loss from operations		(1,377,358	)		(1,521,100	)		(3,191,343	)		(2,596,947	)
Interest expense		—			(20,534	)		(2,697,507	)		(284,557	)
Net valuation change of instruments measured at fair value		31,716			(116,809	)		(93,858	)		(129,763	)
Loss on notes extinguishment		—			(553,447	)		—			(553,447	)
Loss before income taxes		(1,345,642	)		(2,211,890	)		(5,982,708	)		(3,564,714	)
Provision for income taxes		—			—			—			—
Net loss	$	(1,345,642	)	$	(2,211,890	)	$	(5,982,708	)	$	(3,564,714	)

Net loss per share:
Basic and diluted	$	(0.10	)	$	(0.20	)	$	(0.43	)	$	(0.34	)
Number of shares used in per share calculations:
Basic and diluted		13,904,429			10,971,425			13,780,509			10,360,696

See accompanying notes to condensed financial statements

NeuroOne Medical Technologies Corporation

Condensed Statements of Changes in Stockholders’ Deficit

(unaudited)

					Additional						Total
	Common Stock				Paid–In			Accumulated			Stockholders’
	Shares		Amount		Capital			Deficit			Equity (Deficit)
Balance at September 30, 2018		9,656,505	$	9,657	$	6,052,161		$	(10,457,710	)	$	(4,395,892	)
Issuance of common stock under 2018 and 2019 private placements		330,000		330		601,319			—			601,649
Issuance of warrants under 2018 and 2019 private placements		—		—		223,351			—			223,351
Issuance costs related to 2018 and 2019 private placements		—		—		(149,316	)		—			(149,316	)
Issuance of common stock for consulting services		50,000		50		114,950			—			115,000
Net loss		—		—		—			(1,352,824	)		(1,352,824	)
Balance at December 31, 2018		10,036,505		10,037		6,842,465			(11,810,534	)		(4,958,032	)
Issuance of common stock under 2019 private placement		1,743,979		1,744		3,164,640			—			3,166,384
Issuance of warrants under 2019 private placements		—		—		1,193,564			—			1,193,564
Issuance costs related to 2019 and 2018 private placements		—		—		(698,777	)		—			(698,777	)
Issuance of common stock upon conversion of convertible promissory notes		839,179		839		1,920,881			—			1,921,720
Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes		—		—		1,565,402			—			1,565,402
Share–based compensation — employee		—		—		30,085			—			30,085
Share–based compensation — non–employee		—		—		16,569			—			16,569
Exercise of stock options		93,555		94		3,179			—			3,273
Exercise of warrants		231,296		231		416,102			—			416,333
Net loss		—		—		—			(2,211,890	)		(2,211,890	)
Balance at March 31, 2019		12,944,514	$	12,945	$	14,454,110		$	(14,022,424	)	$	444,631

Balance at September 30, 2019		13,493,705	$	13,494	$	15,987,799		$	(17,238,871	)	$	(1,237,578	)
Issuance of common stock under securities purchase agreement		141,666		142		254,858			—			255,000
Issuance of warrants in connection with convertible notes offering		—		—		419,635			—			419,635
Stock-based compensation		—		—		463,084			—			463,084
Issuance of common stock for consulting services		90,000		90		124,503			—			124,593
Issuance of common stock upon vesting of restricted stock units		10,503		11		(11	)		—			—
Net loss		—		—		—			(4,637,066	)		(4,637,066	)
Balance at December 31, 2019		13,735,874		13,737		17,249,868			(21,875,937	)		(4,612,332	)

Conversion of convertible notes into common stock		60,847		61		239,461			—			239,522
Exercise of stock options		42,525		42		1,446			—			1,488
Stock-based compensation		—		—		88,806			—			88,806
Issuance of common stock for consulting services		61,000		61		153,520			—			153,581
Issuance of common stock upon vesting of restricted stock units		122,177		122		289,272			—			289,394
Net loss		—		—		—			(1,345,642	)		(1,345,642	)
Balance at March 31, 2020		14,022,423	$	14,023	$	18,022,373		$	(23,221,579	)	$	(5,185,183	)

See accompanying notes to condensed financial statements

NeuroOne Medical Technologies Corporation

Condensed Statements of Cash Flows

(unaudited)

	For the six months ended March 31,
	2020			2019
Operating activities
Net loss	$	(5,982,708	)	$	(3,564,714	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation		20,965			10,622
Stock-based compensation		1,119,458			189,197
Non-cash interest on convertible notes		1,831,940			51,333
Non-cash discount amortization on convertible notes		—			233,224
Revaluation of convertible notes		93,858			—
Revaluation of premium conversion derivatives and warrant liability		—			129,763
Issuance costs attributed to financing activities		865,567			—
Loss on notes extinguishment		—			553,447
Lease liability principal payment deferral		4,038
Right-of-use asset depreciation adjustment		(4,038	)
Change in assets and liabilities:
Prepaid and other assets		(40,303	)		(74,574	)
Accounts payable and other accrued liabilities		(383,855	)		(104,578	)
Net cash used in operating activities		(2,475,078	)		(2,576,280	)
Investing activities
Purchase of fixed assets and intangible assets		(40,224	)		(65,000	)
Net cash used in investing activities		(40,224	)		(65,000	)
Financing activities
Proceeds from issuance of convertible promissory notes		3,234,800			—
Issuance costs related to convertible notes		(417,176	)		—
Proceeds from unsecured loans		—			245,000
Proceeds from issuance of common stock in connection with private placements		255,000			3,768,032
Proceeds from issuance of warrants in connection with private placements		—			1,416,915
Exercise of warrants		—			416,333
Exercise of stock options		1,488			3,273
Repayment of unsecured loans		—			(299,000	)
Issuance costs related to private placements		(72,315	)		(617,134	)
Net cash provided by financing activities		3,001,797			4,933,419
Net increase in cash		486,495			2,292,139
Cash at beginning of period		260,749			13,260
Cash at end of period	$	747,244		$	2,305,399
Supplemental non-cash financing and investing transactions:
Conversion of convertible promissory notes to equity	$	—		$	1,678,361
Exercise of premium conversion derivative liability	$	—		$	419,590
Reclassification of warrant liability to equity	$	—		$	835,723
Unpaid issuance costs attributed to convertible notes and private placement	$	28,756		$	230,959
Broker warrants issued in connection with convertible notes	$	419,635		$	—
Purchased fixed assets in accounts payable and accrued expenses	$	2,500		$	—
Operating lease right of use asset obtained in exchange for operating lease	$	335,119		$	—

See accompanying notes to condensed financial statements

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

NOTE 1 – Description of Business and Basis of Presentation

NeuroOne Medical Technologies Corporation (the “Company”), a Delaware Corporation, is an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson’s disease, essential tremors, and other brain related disorders.

To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology. The Company received clearance to market the initial device and expect to submit for additional clearance for a second product by end of year. The Company is also evaluating different options for commercializing the current approved device.

The Company is based in Eden Prairie, Minnesota.

COVID-19

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) as a global pandemic, which continues to spread throughout the United States and around the world. As a result of the COVID-19 pandemic, the Company has experienced delays and disruptions in its pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, and research and development operations. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic may impact our business and pre-clinical and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic may also impact the Company’s ability to secure additional financing or its ability to up-list from its current OTC Market (“OTCQB”), and may result in further modifications to its debt agreements. See NOTE 12 – Subsequent Events. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company’s results of future operations, financial position, and liquidity in fiscal year 2020.

Basis of presentation

The accompanying condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended September 30, 2019 included in the Annual Report on Form 10-K. The condensed balance sheet at September 30, 2019 was derived from the audited financial statements of the Company.

In December 2019, the Company merged its wholly owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the Company’s wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company did not have any remaining entities that required consolidation for financial statement reporting purposes.

In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.

NOTE 2 – Going Concern

The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and has negative working capital, negative cash flows from operations, and an accumulated deficit of $23,221,579 as of March 31, 2020. The Company has not established a source of revenues to cover its operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

The Company does not have adequate liquidity to fund its operations without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, these actions are not solely within the control of the Company. If the Company is unable to raise additional funds, or the Company’s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company’s operations. If management is unable to obtain the necessary capital, it may have to cease operations.

NOTE 3 – Summary of Significant Accounting Policies

Management’s Use of Estimates

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company’s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2020, the Company did have deposits in excess of federally insured amounts by $497,244.

Common Stock Valuation

The Company has been utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company’s common stock since September 30, 2019. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the “AICPA Valuation Framework”). The valuation methodology included estimates and assumptions that required the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates.

The fair value the Company’s common stock is used as an input into the fair value determination of instruments recorded at fair value and stock option or other equity awards that the Company has issued.

Fair Value of Financial Instruments

The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

●	Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

●	Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

●	Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

As of March 31, 2020 and September 30, 2019, the fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the convertible notes outstanding during the three and six month period ended March 31, 2020 were based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.

The estimated fair value of the convertible promissory notes of the Company that were outstanding during the three and six month period ended March 31, 2019 were based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes outstanding during fiscal 2019 were based on both the estimated fair value of our common stock and cash flow models discounted at the then current implied market rates evidenced in arms-length transactions representing expected returns by market participants for similar instruments during that period and were based on Level 3 inputs.

There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019.

The fair value of financial instruments measured on a recurring basis is as follows:

	As of March 31, 2020
Description	Total		Level 1		Level 2		Level 3
Liabilities:
Convertible Notes	$	4,921,076		—		—	$	4,921,076
Total liabilities at fair value	$	4,921,076		—		—	$	4,921,076

The following table provides a roll-forward of the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the six month periods ended March 31 as follows:

	2020
Convertible notes
Balance as of beginning of period – September 30, 2019	$	—
Fair value attributed to convertible promissory notes upon issuance		5,066,740
Conversion of convertible promissory notes to common stock		(239,522	)
Change in fair value including accrued interest		93,858
Balance as of end of period – March 31, 2020	$	4,921,076

	2019
Warrant liability
Balance as of beginning of period – September 30, 2018	$	817,155
Change in fair value of warrant liability		18,568
Reclassification to equity upon conversion of convertible promissory notes		(835,723	)
Balance as of end of period – March 31, 2019	$	—

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

	2019
Premium debt conversion derivatives
Balance as of beginning of period – September 30, 2018	$	308,395
Change in fair value of premium debt conversion derivatives		111,195
Reclassification to equity upon conversion of convertible promissory notes		(419,590	)
Balance as of end of period – March 31, 2019	$	—

Intellectual Property

The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.

Property and Equipment

Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.

Impairment of Long-Lived Assets

The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.

Debt Issuance Costs

Debt issuance costs are recorded as a reduction of the convertible promissory notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed statements of operations.

Research and Development Costs

Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (ASC) 730, Research and Development. Lastly, de minimis income from the sale of prototype products and related materials is offset against research and development expenses.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

Warrant Liability

The Company issued warrants to purchase equity securities in connection with the issuance or amendment of the convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders’ (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the condensed statements of operations.

Premium Debt Conversion Derivatives

The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of operations based on the fair value of its common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.

Income Taxes

For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

Net Loss Per Share

For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.

Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s convertible promissory notes, warrants, stock options and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and six month periods ended March 31, 2020 and 2019.

The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and six month periods ended March 31, 2020 and 2019:

	2020		2019
Warrants		8,389,987		6,448,613
Stock options		1,355,512		600,209
Restricted stock units		59,090		—
Convertible notes		1,648,287		—

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

Recent Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company adopted the new standard on October 1, 2019 and did not have a material impact on the Company’s statements of comprehensive loss or statements of cash flows for agreements in place as of the adoption date. As such, the Company did not restate comparative periods and did not recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company elected the short-term lease expedient upon adoption of the standard. See NOTE 4 – Commitments and Contingencies with regard to a new operating lease that commenced after the adoption date on November 1, 2019.

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December 15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new guidance on October 1, 2019, and the new guidance did not have an impact on the Company’s financial statements as of the adoption date.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13). The new guidance modifies the disclosure requirements in Topic 820 as follows:

	●	Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.

	●	Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.

●

Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.

This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance and does not expect that it will have a material impact on its financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial statements.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

NOTE 4 – Commitments and Contingencies

WARF License amendment

The Company entered into an Amended and Restated Exclusive Start-up Company License Agreement (the “WARF License”) with Wisconsin Alumni Research Foundation (“WARF”) on January 21, 2020, which amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1, 2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019.

The WARF License grants to the Company an exclusive license to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. The Company has agreed to pay WARF a royalty equal to a single-digit percentage of its product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. If the Company or any of its sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by the Company if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License.

WARF may terminate the WARF License if the Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, or breaches any other covenant in the WARF License and fails to remedy such default in ninety (90) days or in the event of certain bankruptcy events involving the Company. WARF may also terminate the WARF License on ninety (90) days’ notice if the Company fails to have commercial sales of one or more FDA-approved products under the WARF License by June 30, 2020. The WARF License otherwise expires by its terms (i) on the date that no valid claims on the patents licensed thereunder remain or (ii) upon the cessation for more than four (4) calendar quarters of the payment, once begun, of earned royalties under certain sections of the WARF License. The Company expects the latest expiration of a licensed patent to occur in 2030.

In addition, WARF reserves the right to grant non-profit research institutions and government agencies non-exclusive licenses to practice and use the inventions of the licensed patents for non-commercial research purposes, and the Company grants WARF a non-exclusive, sub licensable, royalty-free right and license for non-commercial research purposes to use improvements to the licensed patents. In the event that the Company discontinues use or commercialization of the licensed patents or improvements thereon, the Company must grant WARF an option to obtain a non-exclusive, sub-licensable royalty-bearing license to use the improvements for commercial purposes.

Legal

From time to time, the Company is subject to litigation and claims arising in the ordinary course of business. In May 2017, NeuroOne received a letter from PMT Corporation (“PMT”), the former employer of Mark Christianson and Wade Fredrickson. PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer’s prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with contracts. The letter, which purported to attach a noncompete agreement signed by Mr. Fredrickson, demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne’s systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer.

On March 29, 2018, the Company was served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. The complaint purported to attach Mr. Fredrickson’s noncompete agreement as Exhibit A. In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT’s contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition. PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys’ fees, costs and interest.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

In April 2019, PMT served the Company, NeuroOne, Inc and Christianson with a proposed Second Amended Complaint, which included new claims against the Company and NeuroOne, Inc for tortious interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne Inc. and Christianson. On June 28, 2019 the Company presented evidence indicating that PMT had participated in a fraud on the Court and sought an Order that PMT had waived the attorney client privilege.

On July 16, 2019, the defendants served PMT with a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal of the case and an award of attorneys’ fees. The Company, NeuroOne Inc and Mr. Christianson further intend to move for summary judgment on all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process.

On August 30, 2019, the Hennepin County District Court heard dispositive motions in this case. The district court judge indicated some claims would likely be tried to a jury and encouraged the parties to settle.

On September 12, 2019 the district court heard NeuroOne’s motion for sanctions. The district court held the sanctions hearing on December 17, 2019 and December 18, 2019 and indicated that a ruling would be made in approximately 90 days. NeuroOne and Mark Christianson (who has not worked for PMT since February 2012) intend to continue to defend themselves vigorously. The Court issued multiple rulings on the Company’s request for summary judgment and sanctions against PMT in April 2020. See NOTE 12 – Subsequent Events.

Facility Lease

On October 7, 2019, the Company entered into a non-cancellable lease agreement (the “Lease”) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the “Landlord”) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the “Term”). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.

Prior to the October 2019 Lease, the Company entered into a non-cancellable facility lease for its operations and headquarters for an eleven month term beginning on December 1, 2018. The monthly rent under that lease was $4,763.

During the three month periods ended March 31, 2020 and 2019, rent expense associated with the facility leases amounted to $25,862 and $14,289, respectively, and $47,866 and $19,052 during the six month periods ended March 31, 2020 and 2019, respectively.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

Supplemental cash flow information related to the operating lease was as follows:

	Six months ended
	March 31, 2020

Cash paid for amounts included in the measurement of lease liability:
Operating cash flows from operating leases	$	—

Right-of -use assets obtained in exchange for lease obligations:
Operating leases	$	335,119

Supplemental balance sheet information related to the operating lease was as follows:

	As of
	March 31, 2020
Right-of-use assets	$	308,055

Lease liability	$	339,157

Weighted average remaining lease term (years)		5.0
Weighted average discount rate		7.0	%

Maturity of the lease liability was as follows:

	As of
	March 31, 2020
2020 (period from April 1, 2020 to September 30, 2020)	$	38,462
2021		77,884
2022		79,832
2023		81,827
2024		83,873
2025		42,454
Total lease payments		404,332
Less imputed interest		(65,175	)
Total		339,157
Short-term portion		(54,922	)
Long-term portion	$	284,235

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

NOTE 5 – Intangibles and Property and Equipment

Intangibles

Intangible assets rollforward is as follows:

	Useful Life
Net Intangibles, September 30, 2019	12-13 years	$	178,838
Less: amortization			(11,158	)
Net Intangibles, March 31, 2020		$	167,680

Amortization expense was $5,579 and $5,311 for the three months ended March 31, 2020 and 2019, respectively, and 11,158 and $10,622 for the six months ended March 31, 2020 and 2019, respectively.

Property and Equipment

Property and equipment held for use by category are presented in the following table:

	As of
	March 31, 2020			September 30, 2019
Equipment and furniture	$	99,181		$	56,457
Software		1,895			1,895
Total property and equipment		101,076			58,352
Less accumulated depreciation		(16,133	)		(6,326	)
Property and equipment, net	$	84,943		$	52,026

Depreciation expense was $5,488 and zero for the three months ended March 31, 2020 and 2019, respectively, and $9,807 and zero for the six months ended March 31, 2020 and 2019, respectively.

NOTE 6 - Accrued Expenses

Accrued expenses consisted of the following at March 31, 2020 and September 30, 2019:

	As of
	March 31, 2020		September 30, 2019
Legal services	$	—	$	228,709
Accrued issuance costs		50,400		50,400
Accrued payroll		126,001		171,087
Lease liability, short-term		54,922		—
Other		60,551		167,525
	$	291,874	$	617,721

The “other” category is primarily comprised of board fees.

NOTE 7 – Convertible Promissory Notes and Warrant Agreements

	As of March 31, 2020		As of September 30, 2019
Paulson convertible notes, principal	$	3,085,200	$	—
Accrued interest		152,036		—
Fair value adjustments		1,683,840		—
	$	4,921,076	$	—

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

Paulson Convertible Note Offering

On November 1, 2019, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the “2019 Paulson Private Placement”), agreed to issue and sell to the investors 13% convertible promissory notes (each, a “2019 Paulson Note” and collectively, the “2019 Paulson Notes”) and warrants (each, a “2019 Paulson Warrant” and collectively, the “2019 Paulson Warrants”) to purchase shares of the Company’s common stock.

The initial closing of the 2019 Paulson Private Placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued the 2019 Paulson Notes in an aggregate principal amount of $3,234,800 to the subscribers for gross proceeds equaling the principal amount. The 2019 Paulson Private Placement terminated on December 3, 2019.

The 2019 Paulson Notes bear interest at a fixed rate of 13% per annum and originally required the Company to repay the principal and accrued and unpaid interest thereon on May 1, 2020. The 2019 Paulson Notes were amended in April 2020 to extend the maturity date to November 1, 2020. See NOTE 12 – Subsequent Events for amended terms under the 2019 Paulson Notes.

Interest on principal amounted to $100,269 and $154,144 during the three and six month periods ended March 31, 2020, respectively, and was recorded under the net valuation change of instruments measured at fair value in the condensed statements of operations. The subscriber has the option to convert the outstanding principal and accrued and unpaid interest of such subscriber’s 2019 Paulson Note (the “Outstanding Balance”) into common stock in an amount equal to the Outstanding Balance divided by the ten day volume weighted average closing price (“VWAP”) of the common stock prior to conversion. In addition, if the Company raises more than $3,000,000 in an equity financing (the “2019 Qualified Financing”) before the maturity date, each subscriber shall have the option to convert the Outstanding Balance into the securities issued by the Company in such 2019 Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the 2019 Qualified Financing or (B) the ten day VWAP of the common stock prior to the first closing of a 2019 Qualified Financing. If a change of control transaction occurs prior to a 2019 Qualified Financing or the maturity date, the 2019 Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company’s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company’s assets.

The Company elected to account for the 2019 Paulson Notes on a fair value basis under ASC 825 to comprehensively value and streamline the accounting for the embedded conversion options. The fair value of the 2019 Paulson Notes was significantly higher than the proceeds received as of each of the respective issuance dates given the significant redemption discount associated with the 2019 Qualified Financing provision. The excess of fair value over proceeds at issuance amounted to $1,831,940 and was recorded to interest expense in the condensed statements of operations during the six month period ended March 31, 2020. Subsequent to issuance, the fair value change of the 2019 Paulson Notes amounted to a reduction of $(31,716) and an increase of $93,858 during the three and six month periods ended March 31, 2020, respectively, and was recorded under the net valuation change of instruments measured at fair value in the condensed statements of operations.

Each 2019 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2019 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. As of the final closing on December 3, 2019, the Company issued 2019 Paulson Warrants exercisable for 864,913 shares of common stock in connection with all closings of the 2019 Paulson Private Placement. The 2019 Paulson Warrants are immediately exercisable and expire on November 1, 2022. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein. The 2019 Paulson warrants were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2019 Paulson Notes exceeded the proceeds received at issuance, there was no value attributed to the 2019 Paulson Warrants in the condensed financial statements.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

In connection with the 2019 Private Placement, Paulson Investment Company, LLC (“Paulson”) received a cash commission equal to 12% of the gross proceeds from the sale of the 2019 Paulson Notes, and 10-year warrants to purchase an amount of Common Stock equal to 259,476 shares of common stock at an exercise price equal to $1.87 per share (the “Broker Warrants”). The issuance costs incurred during the six months ended March 31, 2020 in connection with the 2019 Paulson Private Placement were $865,567. Issuance costs included cash commissions equal to $388,176 and legal and third party fees in the amount of $57,756. In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. There were no issuance costs incurred in connection with 2019 Paulson Notes during the three months ended March 31, 2020. The issuance costs were recorded as a component of interest in the accompanying condensed statements of operations.

During the six months ended March 31, 2020, 2019 Paulson Notes with a fair value of $239,522 were converted into 60,847 shares of common stock.

2017 Convertible Notes

From October 2017 to May 2018, the Company issued convertible notes (the “2017 Convertible Notes”) in an aggregate principal amount of $1,540,000 that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company’s capital stock (the “2017 Warrants”).

On February 28, 2019, the 2017 Convertible Notes were converted into 839,179 shares of common stock and 839,179 common stock purchase warrants with an exercise term of approximately 4.8 years and an exercise price $3.00 per share. In addition, the previously issued 2017 Warrants became immediately exercisable for 839,179 shares of common stock. The conversion was accounted for as a debt extinguishment given the bifurcation of the embedded premium debt conversion feature. The fair value of the newly issued common shares and warrants associated with the 2017 Convertible Notes conversion relative to the carrying value of the debt and fair value of warrant liability and premium derivative liability on the conversion date was $553,447 and was recorded as a loss on note extinguishment in the accompanying condensed statements of operations for the three and six months ended March 31, 2019.

During the three and six month periods ended March 31, 2019, interest on the principal was $20,534 and $51,333, respectively, and interest related to amortization of discounts related to the bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amounted to zero and $233,224, respectively. The fair value changes related to the underlying premium conversion derivative and warrant liability amounted to an expense of $116,809 and $129,763 during the three and six month periods ended March 31, 2019, respectively.

As noted above, the 2017 Convertible Notes were converted into shares of common stock and not outstanding during the three and six month periods ended March 31, 2020.

NOTE 8 – Defined Contribution Plan

The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through March 31, 2020.

Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee’s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee’s date of hire. No matching contributions were made during the three and six month periods ended March 31, 2020. During the six month period ended March 31, 2019, there was a benefit reduction adjustment of $(4,359) given an overpayment. There were no matching contributions during the three month period ended March 31, 2019.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

NOTE 9 – Stock-Based Compensation

Stock-based compensation expense was included in general and administrative and research and development expenses as follows in the accompanying condensed statements of operations:

	Three Months Ended				Six Months Ended
	March 31,				March 31,
	2020		2019		2020		2019
General and administrative	$	495,690	$	26,105	$	1,059,458	$	141,105
Research and development		36,091		44,112		60,000		48,092
Total share-based compensation	$	531,781	$	70,217	$	1,119,458	$	189,197

Stock Options

During the three month period ended March 31, 2020 and 2019, under the 2017 Equity Incentive Plan (the “2017 Plan”), the Company granted 20,000 and 150,548 stock options, respectively, to its employees, consultants and scientific advisory board members. During the six month periods ended March 31, 2020 and 2019, under the 2017 Plan, the Company granted 820,000 and 325,548 stock options, respectively, to its employees, consultants and scientific advisory board members. Vesting generally occurs over an immediate to 48 month period based on a time of service condition although vesting acceleration is provided under one grant in the event that certain milestones are met. The grant date fair value of the grants issued during the three month periods ended March 31, 2020 and 2019 was $1.15 and $1.11 per share, respectively. The grant date fair value of the grants issued during the six month periods ended March 31, 2020 and 2019 was $1.06 and $1.12 per share, respectively. The total expense for the three months ended March 31, 2020 and 2019 related to stock options was $88,806 and $46,654, respectively. The total expense for the six month periods ended March 31, 2020 and 2019 related to stock options was $526,888 and $46,654, respectively. The total number of stock options outstanding as of March 31, 2020 and September 30, 2019 was 1,355,512 and 845,840, respectively.

The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and six month periods ended March 31, 2020 and 2019:

	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2020			2019			2020			2019

Expected stock price volatility		54.3	%		50.7	%		52.8	%		50.2	%
Expected life of options (years)		5.4			6.0			5.7			5.9
Expected dividend yield		0	%		0	%		0	%		0	%
Risk free interest rate		1.4	%		2.6	%		1.7	%		2.7	%

During the three and six month periods ended March 31, 2020, 46,865 and 422,694 stock options vested, respectively, and 39,675 stock options vested during the three and six months ended March 31, 2019. During the three and six month periods ended March 31, 2020, 260,306 and 267,803 stock options were forfeited, respectively, and no options were forfeited during the three and six month periods ended March 31, 2019.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

Restricted Stock Units

During the three and six month periods ended March 31, 2020, 167,851 restricted stock units (“RSUs”) were granted. During the three and six month periods ended March 31, 2019, no RSUs were granted. During the three and six month periods ended March 31, 2020, 122,767 and 133,272 RSUs vested, respectively. No RSUs vested during the three and six month periods ended March 31, 2019. The total expense for the three and six month period ended March 31, 2020 related to the RSU’s was $289,394 and $314,395, respectively. No expense was recognized related to the RSUs during the three and six month periods ended March 31, 2019. The number of RSUs forfeited during the three and six month periods ended March 31, 2020 was zero and 7,003, respectively. No RSUs were forfeited during the three and six month periods ended March 31, 2019.

Other Stock-Based Awards

In October 2019, two consulting agreements were executed whereby up to 115,000 shares of common stock were issuable of which 90,000 shares of common stock were issued and vested as of March 31, 2020 under these agreements. Vesting is based on a time-based vesting condition ranging over a three to nine month period commencing upon the execution of the consulting agreements. In February 2020, an additional consulting agreement was executed whereby up to 90,000 shares of common stock were issuable of which 36,000 shares of common stock were issued and vested as of March 31, 2020 under this agreement. Compensation expense related to the stock awards granted under these consulting agreements amounted to $153,581 and $278,175 and was included in the total stock-based expense referenced above for the three and six month periods ended March 31, 2020, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which ranged from $2.00 to $2.65 per share.

In February 2018, 250,000 shares of common stock were reserved as a result of a consulting agreement for investor relations services executed in February 2018. Under the agreement, zero and 50,000 shares of common stock were awarded during the three and six month period ended March 31, 2019, respectively, on a time-based vesting condition that was met in November 2018. The compensation expense related to the vested common shares was included in the total stock-based expense referenced above which totaled zero and $115,000 for the three and six month periods ended March 31, 2019, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which was $2.30 per share. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.

As of March 31, 2019, the Company had formal obligation to issue future common stock options relating to several consulting agreements. The corresponding stock-based compensation expense related to the stock-based award liabilities amounted to $23,563 and $27,543 during the three and six month periods ended March 31, 2019, respectively, and was included in general and administrative expense in the accompanying condensed statements of operations.

General

As of March 31, 2020, 2,063,506 shares were available for future issuance on a combined basis under the 2016 Equity Incentive Plan and 2017 Plan. Unrecognized stock-based compensation was $0.8 million as of March 31, 2020. The unrecognized share-based expense is expected to be recognized over a weighted average period of 2.9 years.

NOTE 10 – Income Taxes

The effective tax rate for the three and six months ended March 31, 2020 and 2019 was zero percent. As a result of the analysis of all available evidence as of March 31, 2020 and September 30, 2019, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported no income tax benefit during the three and six months ended March 31, 2020 and 2019. If the Company’s assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense. If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes modifications to the limitation on business interest expense and net operating loss provisions, and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act is not expected to have a material impact on the Company’s financial statements. However, the Company is continuing to assess the impact of the CARES Act.

NOTE 11 – Stockholders’ Deficit

Common Stock Offering

On October 23, 2019, the Company entered into Securities Purchase Agreements with certain accredited investors, pursuant to which the Company, in a private placement, has issued and sold 141,666 shares of the Company’s common stock to the accredited investors at a price of $1.80 per share, for gross proceeds amounting to $255,000.

In connection with the private placement, the Company has agreed to issue and sell to accredited investors up to a maximum of 555,555 shares for total gross proceeds to the Company of up to $1,000,000. The Company intends to use the net proceeds from this private placement for funding operations or working capital and general corporate purposes. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the private placement within 60 days of the termination of the private placement.

2019 Private Placement

From December 28, 2018 through July 1, 2019, the Company entered into Subscription Agreements (each, a “2019 Purchase Agreement”) with certain accredited investors (the “New Purchasers”), pursuant to which the Company, in a new private placement (the “2019 Unit Private Placement”), agreed to issue and sell Units (the “2019 Units”), each consisting of (i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”), to the New Purchasers. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Unit Private Placement.

The initial closing of the 2019 Unit Private Placement was consummated on December 28, 2018. The Company issued and sold an aggregate of 2,338,179 of the 2019 Units at $2.50 per Unit to the New Purchasers, for total gross proceeds to the Company of approximately $5,845,448 before deducting offering expenses (1,743,979 and 1,903,979 of the 2019 Units were sold during the three and six month periods ended March 31, 2019, respectively). In connection with the 2019 Unit Private Placement, the Company recorded issuance costs in the amount of $1,150,359 ($722,806 and $812,428 recorded during the three and six month periods ended March 31, 2019, respectively). The 2019 Unit Private Placement was terminated on July 1, 2019.

2018 Private Placement

From July 9, 2018 through November 30, 2018 (the final closing), the Company entered into subscription agreements (each, a “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company, in a private placement (the “2018 Private Placement”), agreed to issue and sell to the Purchasers units (each, a “2018 Unit”), each consisting of (i) 1 share (each, a “Share”) of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”). The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying condensed balance sheets based on their relative fair value to the underlying common shares issued. The initial closing of the 2018 Private Placement was consummated on July 9, 2018 and was terminated on December 12, 2018.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

As of the termination of the 2018 Private Placement on December 12, 2018, the Company had issued and sold an aggregate of 615,200 of the 2018 Units at a price of $2.50 per Unit to the Purchasers, for total gross proceeds to the Company of $1,538,000 before deducting offering expenses (zero and 170,000 of the 2018 Units were sold during the three and six month periods ended March 31, 2019, respectively). In connection with the 2018 Private Placement, the Company recorded issuance costs in the amount of $173,067 (a reduction adjustment of $(24,029) and a cost of $35,665 recorded during the three and six month periods ended March 31, 2019, respectively).

Warrant Activity and Summary

The following table summarizes warrant activity during the six month period ended March 31, 2020:

			Exercise Price		Weighted Average		Weighted Average
	Warrants		Per Warrant		Exercise Price		Term (years)
Outstanding and exercisable at September 30, 2019		7,265,598	$	1.80 - 3.00	$	2.55		3.60
Issued		1,124,389	$	1.87	$	1.87		4.26
Exercised		—	$	—	$	—		—
Forfeited		—	$	—	$	—		—
Outstanding and exercisable at March 31, 2020		8,389,987	$	1.80 - 3.00	$	2.45		3.26

NOTE 12 – Subsequent Events

Amendment of 2019 Paulson Notes

On April 24, 2020, the Company and holders of a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the “Second Paulson Amendment”) to, among other things:

Extend the Maturity Date – The Second Paulson Amendment extends the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either case, unless a change of control transaction happens prior to such date);

ii.

Revise Optional Conversion Terms – The Second Paulson Amendment provides that the amount of shares to be received upon the a subscriber’s optional conversion of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) will be equal to: (1) the Outstanding Balance of such subscriber’s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion; and

iii.

Revise the Registration Date – The Second Paulson Amendment provides that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber has converted all or a majority of the Outstanding Balance of such subscriber’s 2019 Paulson Note prior to such date; (2) the final closing a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.

There were no other significant changes to terms under the Second Paulson Amendment.

2019 Paulson Note Conversion

Between April 24, 2020 and May 1, 2020, certain holders elected to convert outstanding principal and accrued and unpaid interest of 2019 Paulson Notes in the amount of $2,633,280 into 2,054,245 shares of common stock.

NeuroOne Medical Technologies Corporation

Notes to Condensed Financial Statements (unaudited)

Paulson 2020 Convertible Note Financing

On April 30, 2020, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the “2020 Paulson Private Placement”), agreed to issue and sell to the investors up to $3 million of 13% convertible promissory notes (each, a “2020 Paulson Note” and collectively, the “2020 Paulson Notes”) and warrants (each, a “2020 Paulson Warrant” and collectively, the “2020 Paulson Warrants”) to purchase shares of the Company’s common stock.

Between April 30, 2020 and May 8, 2020, the Company issued 2020 Paulson Notes in an aggregate principal amount of $2,469,800 to the Subscribers. The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $6,000,000 or a higher amount determined by the Board.

The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the “2020 Qualified Financing”), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the “Outstanding Balance”) shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.

At any time, at the sole election of the holder of such 2020 Paulson Note, all or a portion of the Outstanding Balance may be converted into that number of shares of common stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.

If a change of control transaction occurs prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company’s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company’s assets.

Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction.

In connection with the 2020 Paulson Private Placement, Paulson will receive a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes, and at the final closing of the 2020 Paulson Private Placement, Paulson will receive 7-year warrants to purchase an amount of common stock equal to 15% of the total gross proceeds received by the Company in the 2020 Paulson Private Placement, divided by 1.87 (the “Broker Warrants”). The Broker Warrants will have an exercise price equal to $1.87.

2020 Paulson Note Conversions

Between May 4, 2020 and May 12, 2020, certain Subscribers elected to convert $50,153 of the outstanding principal and interest of such Subscribers’ 2020 Paulson Notes into 38,335 shares of common stock.

Payroll Protection Program

The CARES Act, signed into law in March 2020, established the Paycheck Protection Program (“PPP”). The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments may be made without penalty. In April 2020, the Company received loan funding of approximately $83,333 under the PPP.

Amendment to Veritas Consulting Agreement

On April 22, 2020, the Company entered into an amendment (the “Amendment”) to the Consulting Agreement, by and between the Company and Veritas Consulting Group Inc. (“Veritas”). Pursuant to the Amendment, the Company issued Veritas an additional 35,000 shares in exchange for consulting services.

PMT Litigation

On April 29, 2020, the district court granted the Company’s motion for sanctions. Additionally, the district court granted the Company’s motion for summary judgment in part with respect to the counts for Christianson’s breach of non-confidentiality agreement, Fredrickson’s breach of confidentiality covenants, and the creation of a constructive trust and denied the Company’s motion for summary judgment on all other counts.

NeuroOne Medical Technologies Corporation
Form 10-Q

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes included in Part I “Financial Information”, Item I “Financial Statements” of this Quarterly Report on Form 10-Q (the “Report”) and the audited financial statements and related footnotes included in our Annual Report on Form 10-K for the year ended September 30, 2019.

Forward-Looking Statements

Certain statements contained in this Report are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. We may, in some cases, use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements.

These forward-looking statements reflect our management’s beliefs and views with respect to future events, are based on estimates and assumptions as of the date of this Report and are subject to risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those in these forward-looking statements. We discuss many of these risks in greater detail under Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended September 30, 2019 and subsequent reports filed with or furnished to the Securities and Exchange Commission (the “SEC”). Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Any forward-looking statement made by us in this Report speaks only as of the date hereof or as of the date specified herein. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable laws or regulations.

Overview

We are a medical technology company focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors and other related brain related disorders. Additionally, we are investigating the potential applications of our technology associated with artificial intelligence. We are based in Eden Prairie, Minnesota.

To date, our primary activities have been limited to, and our limited resources have been dedicated to, performing business and financial planning, raising capital, recruiting personnel, negotiating with business partners and the licensors of our intellectual property and conducting research and development activities. Our cortical strip, grid electrode and depth electrode technology are still under development and we have not generated any revenue from commercial sales.

We have incurred losses since inception. As of March 31, 2020, we had an accumulated deficit of $23.2 million, primarily as a result of expenses incurred in connection with our research and development programs, from general and administrative expenses associated with our operations and interest expense, fair value adjustments and loss on extinguishments related to our debt. We expect to continue to incur significant expenses and increasing operating and net losses for the foreseeable future.

NeuroOne Medical Technologies Corporation
Form 10-Q

Our main source of cash to date has been proceeds from the issuances of notes, common stock, warrants and unsecured loans. See “—Liquidity and Capital Resources—Historical Capital Resources” below.

At March 31, 2020, we had $0.7 million in cash deposits. Our existing cash and cash equivalents will not be sufficient to fund our operating expenses through the end of our fiscal year. We need to obtain substantial additional funding in connection with our continuing operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. However, we may be unable to raise additional funds when needed on favorable terms or at all. Our failure to raise such capital as and when needed would have a negative impact on our financial condition and our ability to develop and commercialize our cortical strip, grid electrode and depth electrode technology and future products and our ability to pursue our business strategy. See “—Liquidity and Capital Resources—Funding Requirements and Outlook” below.

Recent Developments

COVID-19

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States and around the world. As a result of the COVID-19 pandemic, the Company has experienced delays and disruptions in our pre-clinical and clinical trials, as well as interruptions in our manufacturing, supply chain, and research and development operations. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic may impact our business and pre-clinical and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic may also impact our ability to secure additional financing or ability up-list from our current OTC Market (“OTCQB”), and may result in further modifications to our debt agreements. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company’s results of future operations, financial position, and liquidity in fiscal year 2020.

Financial Overview

Revenue

To date, we have not generated any revenue. We do not expect to generate revenue unless or until we develop and commercialize our cortical strip, grid electrode and depth electrode technology. If we fail to complete the development of our cortical strip, grid electrode and depth electrode technology, or any other product candidate we may pursue in the future, in a timely manner, or fail to obtain certain regulatory approvals, we may never be able to generate any revenue.

General and Administrative

General and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters, intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters and product costs. We anticipate that our general and administrative expenses will significantly increase in the future to support our continued research and development activities, potential commercialization of our cortical strip, grid electrode and depth electrode technology and the increased costs of operating as a public company. These increases will include increased costs related to the hiring of additional personnel and fees for legal and professional services, as well as other public-company related costs.

Research and Development

Research and development expenses consist of expenses incurred in performing research and development activities in developing our cortical strip, grid electrode and depth electrode technology. Research and development expenses include compensation and benefits for research and development employees including stock-based compensation, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants and other outside expenses. Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. Lastly, de minimis income from the sale of prototype products and related materials are offset against research and development expenses.

NeuroOne Medical Technologies Corporation
Form 10-Q

We expect our research and development expenses to significantly increase over the next several years as we develop our cortical strip, grid electrode and depth electrode technology and conduct pre-clinical testing and clinical trials and will depend on the duration, costs and timing to complete our pre-clinical programs and clinical trials.

Interest Expense

Interest expense primarily consists of amortized discount costs and interest costs as applicable related to our 2019 Paulson Notes and 2017 Convertible Notes while outstanding as described further below.

Net valuation change of instruments measured at fair value

The net valuation change of instruments measured at fair value include the change in fair value of the 2019 Paulson Notes, warrant liability and the premium conversion derivatives during the particular period these instruments are outstanding.

Loss on note extinguishment

Loss on note extinguishment includes the loss associated with debt instrument modifications and conversions accounted for as debt extinguishments.

Results of Operations

Comparison of the Three Months Ended March 31, 2020 and 2019

The following table sets forth the results of operations for the three months ended March 31, 2020 and 2019, respectively.

	For the three months ended March 31, (unaudited)
	2020			2019			Period to Period Change
Operating expenses:
General and administrative	$	1,035,256		$	1,084,789		$	(49,533	)
Research and development		342,102			436,311			(94,209	)
Total operating expenses		1,377,358			1,521,100			(143,742	)
Loss from operations		(1,377,358	)		(1,521,100	)		143,742
Interest expense		—			(20,534	)		20,534
Net valuation change of instruments measured at fair value		31,716			(116,809	)		148,525
Loss on note extinguishment		—			(553,447	)		553,447
Loss before income taxes		(1,345,642	)		(2,211,890	)		866,248
Provision for income taxes		—			—			—
Net loss	$	(1,345,642	)	$	(2,211,890	)	$	866,248

General and administrative expenses

General and administrative expenses were $1.0 million for the three months ended March 31, 2020, compared to $1.1 million for the three months ended March 31, 2019. The decrease was primarily due to a net decrease in legal and accounting fees of $0.2 million, board of director related costs of $0.2 million and employee related expenses of approximately $0.2 million offset in part by an increase in stock-based compensation costs of $0.5 million.

NeuroOne Medical Technologies Corporation
Form 10-Q

Research and development expenses

Research and development expenses were $0.3 million for the three months ended March 31, 2020, compared to $0.4 million during for the three months ended March 31, 2019. The decrease period over period was attributed to the fluctuation in development activities, which primarily included salary-related expenses, consulting services and materials associated with research and development activities.

Interest expense

Interest expense for the three months ended March 31, 2020 and 2019 was zero and $21,000, respectively. Interest expense for the three months ended March 31, 2019 related to interest on note principal in connection to the 2017 Convertible Notes described further below. Interest on principal in connection with the 2019 Paulson Notes is included in the net valuation change of instruments measured at fair value line item.

Net valuation change of instruments measured at fair value:

The net valuation change of instruments measured at fair value for the 2019 Paulson Notes, warrant liability and premium conversion derivatives for the three months ended March 31, 2020 and 2019 was $(32,000) and $0.1 million, respectively. The change is due to accrued interest on the 2019 Paulson Notes and due to fluctuations in our common stock fair value and the number of potential shares of common stock issuable upon conversion of the 2019 Paulson Notes or the 2017 Convertible Notes while outstanding.

Loss on note extinguishment

Non-cash loss on note extinguishment for the six months ended March 31, 2019 was $0.6 million. The Series 3 Notes were converted on February 28, 2019 and the conversion was accounted for as a note extinguishment given the bifurcated embedded premium debt conversion feature. There were no note extinguishments during the comparable period in 2020.

Comparison of the Six Months Ended March 31, 2020 and 2019

The following table sets forth the results of operations for the six months ended March 31, 2020 and 2019, respectively.

	For the six months ended March 31, (unaudited)
	2020			2019			Period to Period Change
Operating expenses:
General and administrative	$	2,347,422		$	1,951,468		$	395,954
Research and development		843,921			645,479			198,442
Total operating expenses		3,191,343			2,596,947			594,396
Loss from operations		(3,191,343	)		(2,596,947	)		(594,396	)
Interest expense		(2,697,507	)		(284,557	)		(2,412,950	)
Net valuation change of instruments measured at fair value		(93,858	)		(129,763	)		35,905
Loss on note extinguishment		—			(553,447	)		553,447
Loss before income taxes		(5,982,708	)		(3,564,714	)		(2,417,994	)
Provision for income taxes		—			—			—
Net loss	$	(5,982,718	)	$	(3,564,714	)	$	(2,417,994	)

NeuroOne Medical Technologies Corporation
Form 10-Q

General and administrative expenses

General and administrative expenses were $2.3 million for the six months ended March 31, 2020, compared to $2.0 million for the six months ended March 31, 2019. The increase was primarily due to a net increase of stock-based compensation of $0.9 million offset in part by a decrease in legal and accounting fees of $0.2 million, board of director related costs of $0.2 million and other employee related costs of approximately $0.1 million.

Research and development expenses

Research and development expenses were $0.8 million for the six months ended March 31, 2020, compared to $0.6 million during for the six months ended March 31, 2019. The increase period over period was attributed to supporting development activities, which primarily included salary-related expenses and costs related to consulting services, materials and supplies.

Interest expense

Interest expense for the six months ended March 31, 2020 and 2019 was $2.7 million and $0.3 million, respectively. The increase was primarily attributed to non-cash interest expense in connection with our 2019 Paulson Notes described further below. Interest expense attributed to the 2019 Paulson Notes was comprised of issuance costs of $0.9 million and day-one interest at issuance of $1.8 million representing the amount by which fair value exceeded note proceeds. Interest on principal in connection with the 2019 Paulson Notes is included in the net valuation change of instruments measured at fair value line item.

Interest expense during the six months ended March 31, 2019 was comprised of interest on principal of $51,000 and amortization of debt discount costs of $0.2 million related to the Series 3 Notes.

Net valuation change of instruments measured at fair value:

The net valuation change of instruments measured at fair value for the 2019 Paulson Notes, warrant liability and premium conversion derivatives for the three months ended March 31, 2020 and 2019 was $94,000 and $0.1 million, respectively. The change is due to accrued interest on the 2019 Paulson Notes and due to fluctuations in our common stock fair value and the number of potential shares of common stock issuable upon conversion of the 2019 Paulson Notes or the 2017 Convertible Notes while outstanding.

Loss on note extinguishment

Liquidity and Capital Resources

Historical Capital Resources

As of March 31, 2020, our principal source of liquidity consisted of cash deposits of $0.7 million. We have not generated any revenue, and we anticipate that we will continue to incur losses for the foreseeable future. We anticipate that our expenses will increase substantially as we develop our cortical strip, grid electrode and depth electrode technology and pursue pre-clinical and clinical trials, seek regulatory approvals, contract to manufacture any products, establish our own sales, marketing and distribution infrastructure to commercialize our cortical strip, grid electrode and depth electrode technology under development, if approved, hire additional staff, add operational, financial and management systems and continue to operate as a public company.

NeuroOne Medical Technologies Corporation
Form 10-Q

Our source of cash to date has been proceeds from the issuances of notes with warrants, common stock with warrants and unsecured loans, the terms of which are further described below.

2020 Paulson Convertible Notes

The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the “2020 Qualified Financing”), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the “Outstanding Balance”) shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price (“VWAP”) of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.

NeuroOne Medical Technologies Corporation
Form 10-Q

2020 Paulson Note Conversions

2019 Paulson Convertible Notes

The initial closing of the private placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued 2019 Paulson Notes in an aggregate principal amount of $3,234,800 to the Subscribers for gross proceeds equaling the principal amount. The private placement terminated on December 3, 2019.

Second Amendment of 2019 Paulson Notes

ii.

Revise Optional Conversion Terms – The Second Paulson Amendment provides that the amount of shares to be received upon the a subscriber’s optional conversion of the 2019 Paulson Notes prior to a Qualified Financing (as defined in the 2019 Paulson Notes) will be equal to: (1) the outstanding balance of such subscriber’s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion; and

iii.

Revise the Registration Date – The Second Paulson Amendment provides that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber has converted all or a majority of the outstanding balance of such subscriber’s 2019 Paulson Note prior to such date; (2) the final closing a Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.

There were no other significant changes to terms under the Second Paulson Amendment.

2019 Paulson Note Conversion

NeuroOne Medical Technologies Corporation
Form 10-Q

Common Stock Offering

Financings Prior to Fiscal Year 2020

Our sources of cash prior to fiscal year 2020 were generated from the following financing arrangements:

2019 Unit Private Placement

From December 28, 2018 through July 1, 2019, the Company entered into Subscription Agreements (each, a “2019 Purchase Agreement”) with certain accredited investors (the “New Purchasers”), pursuant to which the Company, in a new private placement (the “2019 Unit Private Placement”), agreed to issue and sell Units (the “2019 Units”), each consisting of (i) one share of common stock and (ii) a warrant to purchase one share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”), to the New Purchasers. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Unit Private Placement.

2018 Private Placement

From July 9, 2018 through November 30, 2018 (the final closing), the Company entered into subscription agreements (each, a “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company, in a private placement (the “2018 Private Placement”), agreed to issue and sell to the Purchasers units (each, a “2018 Unit”), each consisting of (i) one share of common stock and (ii) a warrant to purchase one share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”). The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying condensed balance sheets based on their relative fair value to the underlying common shares issued. The initial closing of the 2018 Private Placement was consummated on July 9, 2018 and was terminated on December 12, 2018.

Series 3 Notes and Warrants (2017 Convertible Notes)

From October 2017 to May 2018, the Company issued convertible notes (the “Series 3 Notes” or “2017 Convertible Notes”) in an aggregate principal amount of $1.5 million that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company’s capital stock (the “Series 3 Warrants”). On February 28, 2019, the outstanding principal and interest on the Series 3 Notes converted into 839,179 shares of common stock and 839,179 common stock purchase warrants with an exercise term of approximately 4.8 years and an exercise price of $3.00 per share.

NeuroOne Medical Technologies Corporation
Form 10-Q

In addition, each holder has the option to purchase additional shares of our capital stock equal to 839,179 shares of capital stock of the Company at a per share exercise price equal to $2.50. The warrants exercisable at $2.50 per share have a five year term which commenced on February 28, 2019. The exercise price and number of the shares issuable upon exercising the Series 3 Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization, business combination or similar transaction, as described therein.

Series 2 Notes and Warrants

In August 2017, the Company entered into a subscription agreement in an aggregate principal amount of $253,000 to certain accredited investors (the “Series 2 Notes”). On July 2, 2018, the Series 2 Notes were converted into 144,053 shares of Common Stock and warrants exercisable for 477,856 shares of common stock at a per share exercise price equal to $1.80 per share. The warrants expire on November 21, 2021.

Series 1 Notes and Warrants

From November 2016 to June 2017, the Company issued convertible promissory notes in an aggregate principal amount of $1.6 million that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company’s capital stock (the “Series 1 Notes”). The Series 1 Notes were converted into 1,002,258 shares of Common Stock and warrants exercisable for 2,004,516 shares of Common Stock were issued on July 2, 2018 at a per share exercise price of $1.80 per share. The warrants will expire on November 21, 2021.

Unsecured Loans

From March 2018 to December 2018, the Company received gross proceeds from unsecured loans in the amount of $528,000. The unsecured loans were repaid in full as of June 30, 2019.

Refer to “—Liquidity and Capital Resources—Historical Capital Resources” in our Annual Report on Form 10-K for the year ended September 30, 2019 for additional information related to financings prior to fiscal year 2020.

Funding Requirements and Outlook

We have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless, we successfully commercialize our cortical strip, grid electrode and depth electrode technology. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings as well as collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third-party partners, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or through collaborations, strategic alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development, future commercialization efforts, or grant rights to develop and market our cortical strip, grid electrode and depth electrode technology that we would otherwise prefer to develop and market ourselves.

Our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended September 30, 2019 and as of and for the nine month transition period ended September 30, 2018, noting the existence of substantial doubt about our ability to continue as a going concern. This uncertainty arose from management’s review of our results of operations and financial condition and its conclusion that, based on our operating plans, we did not have sufficient existing working capital to fund our operating expenses.

NeuroOne Medical Technologies Corporation
Form 10-Q

As of March 31, 2020, the outstanding principal and accrued and unpaid interest on the 2019 Paulson Notes was $3,237,236. Some of the 2019 Paulson Notes were converted following March 31, 2020; see NOTE 12 – Subsequent Events to our condensed financial statements included in “Part 1, Item 1 – Financial Statements” in this Report. However, if we fail to complete the 2019 Qualified Financing by November 1, 2020, the remaining 2019 Paulson Notes will be immediately due and payable on such date, and we may not have sufficient cash to pay the principal and accrued and unpaid interest thereon.

We have agreements with the Wisconsin Alumni Research Foundation (“WARF”) and the Mayo Foundation for Medical Education and Research (“Mayo”) that require us to make certain milestone and royalty payments.

On January 22, 2020, we entered into an Amended and Restated License Agreement (the “WARF License”) with WARF, which amended and restated in full our prior license agreement with WARF, dated October 1, 2014 (the “Original WARF License”). Under the WARF License, we have agreed to pay WARF a royalty equal to a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. If we or any of our sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License.

Under the Amended and Restated License and Development Agreement with Mayo (the “Mayo Development Agreement”), we have agreed to pay Mayo a royalty equal to a single-digit percentage of our product sales pursuant to the Mayo Development Agreement. Nothing further is due until we start selling our products.

Refer to the Company’s Annual Report on Form 10-K for the year ended September 30, 2019 with regard to: “Item 1—Business—WARF License,” “Business—Mayo Foundation for Medical Education and Research License and Development Agreement,” “Item 1A—Risk Factors—Risks Relating to Our Business—We depend on intellectual property licensed from WARF for our technology under development, and the termination of this license would harm our business” and “Item 1A—Risk Factors—We depend on our partnership with Mayo to license certain know how for the development and commercialization of our technology.”

Our existing cash and cash equivalents will not be sufficient to fund our operating expenses without raising additional funds. To continue to fund operations, we will need to secure additional funding or take steps to reduce expenses. We may obtain additional financing in the future through the issuance of our Common Stock and securities convertible into our Common Stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all. Further, we may not be able to pay off or modify terms of our existing debt, and any failure to raise capital or to amend existing debt that may be due as and when needed could compromise our ability to execute on our business plan.

The development of our cortical strip, grid electrode and depth electrode technology is subject to numerous uncertainties, and we have based these estimates on assumptions that may prove to be substantially different than we currently anticipate and could use our cash resources sooner than we expect. Additionally, the process of developing medical devices is costly, and the timing of progress in pre-clinical tests and clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving certain regulatory approval and then a level of product sales adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

NeuroOne Medical Technologies Corporation
Form 10-Q

Cash Flows

The following is a summary of cash flows for each of the periods set forth below.

	For the Six Months Ended
	March 31,
	2020			2019
Net cash used in operating activities	$	(2,475,078	)	$	(2,576,280	)
Net cash used by investing activities		(40,224	)		(65,000	)
Net cash provided by financing activities		3,001,797			4,933,419
Net increase in cash	$	486,495		$	2,292,139

Net cash used in operating activities

Net cash used in operating activities was $2.5 million for the six months ended March 31, 2020, which consisted of a net loss of $6.0 million partially offset primarily by non-cash interest, stock-based compensation, depreciation, amortization related to intangible assets, revaluation of convertible notes, totaling approximately $3.9 million in the aggregate. The net change in our net operating assets and liabilities associated with fluctuations in our operating activities resulted in a cash use of $0.4 million. The change in operating assets and liabilities was primarily attributable to a decrease in accounts payable and accrued expenses and by an increase in our prepaid expenses.

Net cash used in operating activities was $2.6 million for the six months ended March 31, 2019, which consisted of a net loss of $3.6 million partially offset by non-cash interest, note discount amortization, revaluation of premium debt conversion derivatives and warrant liabilities, non-cash note extinguishment, amortization related to intangible assets and stock-based compensation, totaling approximately $1.2 million in the aggregate. Net loss was also adjusted by a net change of $0.2 million in our net operating assets and liabilities. The change in operating assets and liabilities was primarily attributable to a net decrease in accounts payable and accrued expenses, offset in part by an increase in our prepaid expenses, associated with fluctuations in our operating activities.

Net cash used by investing activities

Net cash used by investing activities was $40,000 and consisted of outlays for furniture and equipment during the six months ended March 31, 2020.

Net cash used by investing activities was $0.1 million for the six months ended March 31, 2019 and consisted of the payment owed under the terms of the WARF License related to research and development.

Net cash provided by financing activities

Net cash provided by financing activities was $3.0 million for the six months ended March 31, 2020, which consisted primarily of net proceeds received upon the issuance of the Paulson Notes and common stock offering totaling $3.0 million in the aggregate and proceeds from the exercise of stock options in the amount of $1,000.

Net cash provided by financing activities was $4.9 million for the six months ended March 31, 2019 which consisted primarily of net proceeds received upon the issuance of the 2019 Units and 2018 Units in the 2019 and 2018 Private Placements in the amount of approximately $4.6 million. Additionally, cash provided by financing activities also included proceeds from stock option and warrant exercises in the aggregate of $0.4 million, offset in part by net repayments over proceeds relating to our unsecured loans in the amount of $54,000 during the six month period.

Critical Accounting Policies

Our financial statements are prepared in accordance with U.S. generally accepted accounting principles. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based upon information available to us at the time that we make these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described in Note 3 — “Summary of Significant Accounting Policies” to our condensed financial statements included in “Part 1, Item 1 – Financial Statements” in this Report.

NeuroOne Medical Technologies Corporation
Form 10-Q

During the three and six months ended March 31, 2020, we elected to record the convertible notes issued during the three month period ended March 31, 2020 at fair value which is based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments. There were no additional material changes to our critical accounting policies or estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended September 30, 2019.

Recent Accounting Pronouncements

Refer to Note 3— “Summary of Significant Accounting Policies” to our condensed financial statements included in “Part 1, Item 1 – Financial Statements” in this Report for a discussion of recently issued accounting pronouncements.

Off Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate, to allow timely decisions regarding required disclosure.

We designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Under the supervision of and with the participation of our management, including our principal executive and financial officer, we evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15(d)- 15(e) promulgated under the Exchange Act as of March 31, 2020. Based on this evaluation, our principal executive and financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2020.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended March 31, 2020, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

NeuroOne Medical Technologies Corporation
Form 10-Q

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

On March 29, 2018, we were served with a complaint filed by PMT adding the Company, NeuroOne, Inc. and Mr. Christianson to its existing lawsuit against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota (the “Court”). In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT’s contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the Company and NeuroOne, Inc., PMT alleges that the Company and NeuroOne, Inc. were unjustly enriched and engaged in unfair competition. PMT asks the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys’ fees, costs and interest. The Company, NeuroOne, Inc. and Mr. Christianson (who has not worked for PMT since 2012) intend to defend themselves vigorously. Furthermore, Mr. Christianson is a key officer and the loss of him would be detrimental to our operations and prospects.

On April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal states that: the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff’s claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition. On January 7, 2019, the judge granted the motion for dismissal with respect to PMT’s claim for breach of the duty of good faith and fair dealing, and denied the motion for dismissal with respect to the other claims presented. Discovery is now virtually complete. On June 28, 2019, the Company presented to the special master evidence of what it believed to reflect significant litigation misconduct by PMT relating to a manufactured non-compete agreement for Wade Fredrickson that it had attempted to pass off as a business record of PMT. Based on the evidence presented, the special master ruled that PMT had waived the attorney client privilege with respect to certain communications with respect to the Fredrickson non-compete with both its former and current litigation counsel and authorized a deposition of the former litigation counsel concerning these communications. On August 30, 2019 the Hennepin County District Court heard dispositive motions in this case. The district court judge indicated some claims would likely be tried to a jury and encouraged the parties to settle.

Item 1A. Risk Factors

In addition to the other information set forth elsewhere in this Report, you should carefully consider the factor set forth below and the other factors discussed in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended September 30, 2019. Those factors, if they were to occur, could cause our actual results to differ materially from those expressed in our forward-looking statements in this Report, and materially adversely affect our financial condition or future results. Although we are not aware of any other factors that we currently anticipate will cause our forward-looking statements to differ materially from our future actual results, or materially affect the Company’s financial condition or future results, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial might materially adversely affect our actual business, financial condition and/or operating results.

The COVID-19 pandemic could adversely impact our business, including pre-clinical and clinical trials and regulatory approvals.

In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, COVID-19 had spread to other countries, including the United States, and was declared to be a pandemic by the World Health Organization. Efforts to contain the spread of COVID-19 have intensified, and the United States, Europe and Asia have implemented severe travel restrictions, social distancing and “shelter-in-place” orders, and delays or cancellations of elective surgeries. The COVID-19 pandemic poses the risk that the Company, our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time due to shutdowns that may be requested or mandated by state and federal governmental authorities.

As COVID-19 continues to spread around the globe, we will likely experience disruptions that could severely impact our business and planned clinical trials, including:

●

delays or difficulties in conducting pre-clinical and clinical trials;

●

interruption in global manufacturing and shipping that may affect the transport of clinical trial materials and materials, including testing equipment and personal protective equipment, used at our facilities;

●

changes in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the way in which clinical trials are conducted and may result in unexpected costs;

●

delay in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention to approval of other therapeutics or other activities related to COVID-19;

●

impact our ability to secure additional financing, our ability to up-list from our current OTC Market (“OTCQB”); and

●

may result in further modifications to our debt agreements.

In addition, the outbreak of COVID-19 could disrupt our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our office or laboratory facilities, or due to quarantines. COVID-19 illness could also impact members of our Board and its ability to hold meetings.

NeuroOne Medical Technologies Corporation
Form 10-Q

The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact our business and pre-clinical and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

All unregistered issuances of securities during the period covered by this Report have been previously disclosed in the Company’s current reports on Form 8-K.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable to our Company.

Item 5. Other Information

None.

NeuroOne Medical Technologies Corporation
Form 10-Q

Item 6. Exhibits

Exhibit 3.1		Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.4 on the Registrant’s Current Report on Form 8-K filed on June 29, 2017)
Exhibit 3.2		Bylaws of the Company (incorporated by reference to Exhibit 3.5 on the Registrant’s Current Report on Form 8-K filed on June 29, 2017)
Exhibit 10.1+		Amended and Restated Exclusive Start-up Company License Agreement effective January 21, 2020 by and between NeuroOne Medical Technologies Corporation and Wisconsin Alumni Research Foundation (incorporated by reference to Exhibit 10.1 on the Registrant’s Current Report on Form 8-K filed on January 24, 2020)
Exhibit 10.2		Form of Broker Warrant (incorporated by reference to Exhibit 4.1 on the Registrant’s Current Report on Form 8-K filed on January 24, 2020)
Exhibit 31		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 101.INS		XBRL Instance Document.
Exhibit 101.SCH		XBRL Taxonomy Extension Schema Document.
Exhibit 101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
Exhibit 101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.
Exhibit 101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
Exhibit 101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
Exhibit 104		XBRL Cover Page

Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain portions of the exhibits that are not material and would be competitively harmful if publicly disclosed have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Copies of the unredacted exhibits will be furnished to the SEC upon request.

NeuroOne Medical Technologies Corporation
Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 14, 2020

NeuroOne Medical Technologies Corporation

By:	/s/ Dave Rosa
	Dave Rosa
	Chief Executive Officer
	(Principal Executive Officer)
	(Principal Financial Officer)

EX-31 2 f10q0320ex31_neuroon.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, David Rosa, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of NeuroOne Medical Technologies Corporation for the period ended March 31, 2020;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 14, 2020	/s/ David Rosa
	Name:	David Rosa
	Title:	Chief Executive Officer
		(Principal Executive Officer and Principal Financial Officer)

EX-32 3 f10q0320ex32_neuroon.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER,

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002*

Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code, David Rosa, Chief Executive Officer of NeuroOne Medical Technologies Corporation (the “Company”) hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2020, to which this Certification is attached as Exhibit 32 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

2. The information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

/s/ David Rosa

David Rosa

Chief Executive Officer

(Principal Executive Officer)

(Principal Financial Officer)

Dated: May 14, 2020

* This certification accompanies the report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NeuroOne Medical Technologies Corporation under the Securities Act of 1933, as amended, or the Exchange Act made before or after the date of the report, irrespective of any general incorporation language contained in such filing.

EX-101.INS 4 nmtc-20200331.xml XBRL INSTANCE FILE 0001500198 2018-09-30 0001500198 us-gaap:CommonStockMember 2018-09-30 0001500198 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001500198 us-gaap:RetainedEarningsMember 2018-09-30 0001500198 us-gaap:WarrantMember 2018-09-30 0001500198 nmtc:DebtConversionDerivativeMember 2018-09-30 0001500198 2019-09-30 0001500198 2019-01-01 2019-03-31 0001500198 nmtc:ConvertiblePromissoryNoteMember 2019-09-30 0001500198 us-gaap:WarrantMember 2019-09-30 0001500198 nmtc:TwoThousandEighteenPrivatePlacementMember 2018-11-20 2018-11-30 0001500198 nmtc:TwoThousandEighteenPrivatePlacementMember 2018-12-12 0001500198 nmtc:TwoThousandEighteenPrivatePlacementMember 2018-12-03 2018-12-12 0001500198 us-gaap:CommonStockMember 2018-12-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001500198 us-gaap:RetainedEarningsMember 2018-12-31 0001500198 2018-10-01 2019-03-31 0001500198 2018-12-31 0001500198 us-gaap:CommonStockMember 2019-09-30 0001500198 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001500198 us-gaap:RetainedEarningsMember 2019-09-30 0001500198 nmtc:StockOptionLiabilityMember 2018-02-28 0001500198 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001500198 us-gaap:CommonStockMember 2019-03-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001500198 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001500198 us-gaap:RetainedEarningsMember 2019-03-31 0001500198 2019-03-31 0001500198 nmtc:ConvertibleDebtOneMember 2019-02-01 2019-02-28 0001500198 us-gaap:FairValueInputsLevel1Member 2020-03-31 0001500198 us-gaap:FairValueInputsLevel2Member 2020-03-31 0001500198 us-gaap:FairValueInputsLevel3Member 2020-03-31 0001500198 2020-03-31 0001500198 us-gaap:WarrantMember 2018-10-01 2019-03-31 0001500198 us-gaap:WarrantMember 2019-03-31 0001500198 us-gaap:WarrantMember 2020-03-31 0001500198 srt:MinimumMember 2019-10-01 2020-03-31 0001500198 srt:MaximumMember 2019-10-01 2020-03-31 0001500198 2020-05-08 0001500198 2019-10-01 2020-03-31 0001500198 nmtc:ConvertibleNotesMember 2019-10-01 2020-03-31 0001500198 nmtc:ConvertibleNotesMember 2019-09-30 0001500198 nmtc:ConvertibleNotesMember 2020-03-31 0001500198 us-gaap:WarrantMember 2019-10-01 2020-03-31 0001500198 nmtc:DebtConversionDerivativeMember 2018-10-01 2019-03-31 0001500198 nmtc:DebtConversionDerivativeMember 2019-03-31 0001500198 us-gaap:WarrantMember 2019-10-01 2020-03-31 0001500198 us-gaap:EmployeeStockOptionMember 2019-10-01 2020-03-31 0001500198 us-gaap:RestrictedStockUnitsRSUMember 2019-10-01 2020-03-31 0001500198 nmtc:ConvertibleNotesMember 2019-10-01 2020-03-31 0001500198 us-gaap:WarrantMember 2018-10-01 2019-03-31 0001500198 us-gaap:EmployeeStockOptionMember 2018-10-01 2019-03-31 0001500198 us-gaap:RestrictedStockUnitsRSUMember 2018-10-01 2019-03-31 0001500198 nmtc:ConvertibleNotesMember 2018-10-01 2019-03-31 0001500198 us-gaap:EquipmentMember srt:MinimumMember 2019-10-01 2020-03-31 0001500198 us-gaap:EquipmentMember srt:MaximumMember 2019-10-01 2020-03-31 0001500198 us-gaap:SoftwareDevelopmentMember 2019-10-01 2020-03-31 0001500198 us-gaap:CommonStockMember 2020-03-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001500198 us-gaap:RetainedEarningsMember 2020-03-31 0001500198 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2020-03-31 0001500198 us-gaap:GeneralAndAdministrativeExpenseMember 2018-10-01 2019-03-31 0001500198 us-gaap:ResearchAndDevelopmentExpenseMember 2019-10-01 2020-03-31 0001500198 us-gaap:ResearchAndDevelopmentExpenseMember 2018-10-01 2019-03-31 0001500198 us-gaap:StockOptionMember 2019-10-01 2020-03-31 0001500198 us-gaap:StockOptionMember 2018-10-01 2019-03-31 0001500198 nmtc:StockOptionLiabilityMember 2019-10-01 2020-03-31 0001500198 nmtc:TwoZeroOneSevenPlanMember 2019-10-01 2020-03-31 0001500198 nmtc:TwoZeroOneSevenPlanMember 2018-10-01 2019-03-31 0001500198 us-gaap:StockOptionMember nmtc:TwoThousandSixteenAndSeventeenPlanMember 2020-03-31 0001500198 us-gaap:RestrictedStockMember 2018-10-01 2019-03-31 0001500198 us-gaap:RestrictedStockMember 2019-10-01 2020-03-31 0001500198 nmtc:StockOptionLiabilityMember 2019-10-15 2019-10-31 0001500198 nmtc:StockOptionLiabilityMember nmtc:ConsultantMember 2019-10-15 2019-10-31 0001500198 nmtc:StockOptionLiabilityMember nmtc:ConsultantOneMember 2019-10-15 2019-10-31 0001500198 nmtc:StockOptionLiabilityMember srt:MinimumMember 2019-10-15 2019-10-31 0001500198 nmtc:StockOptionLiabilityMember srt:MaximumMember 2019-10-15 2019-10-31 0001500198 us-gaap:WarrantMember srt:MinimumMember 2019-10-01 2020-03-31 0001500198 us-gaap:WarrantMember srt:MaximumMember 2019-10-01 2020-03-31 0001500198 nmtc:TwoThousandNineteenPrivatePlacementMember 2018-12-01 2018-12-28 0001500198 nmtc:TwoThousandNineteenPrivatePlacementMember 2018-12-28 0001500198 nmtc:TwoThousandEighteenPrivatePlacementMember 2018-10-01 2019-03-31 0001500198 us-gaap:WarrantMember 2019-10-01 2019-10-23 0001500198 nmtc:TwoThousandNineteenPrivatePlacementMember 2018-10-01 2019-03-31 0001500198 nmtc:ConvertiblePromissoryNoteMember 2020-03-31 0001500198 nmtc:ConvertibleDebtOneMember 2020-03-31 0001500198 us-gaap:ConvertibleNotesPayableMember 2019-11-01 0001500198 us-gaap:ConvertibleNotesPayableMember 2019-12-03 0001500198 us-gaap:ConvertibleNotesPayableMember 2019-10-01 2020-03-31 0001500198 us-gaap:ConvertibleNotesPayableMember 2020-03-31 0001500198 us-gaap:ConvertibleNotesPayableMember 2019-11-20 2019-12-03 0001500198 nmtc:PaulsonPrivatePlacementMember us-gaap:CommonStockMember 2019-10-01 2020-03-31 0001500198 nmtc:PaulsonPrivatePlacementMember us-gaap:CommonStockMember 2020-03-31 0001500198 nmtc:PaulsonPrivatePlacementMember 2019-10-01 2020-03-31 0001500198 nmtc:ConvertibleDebtOneMember 2018-10-01 2019-03-31 0001500198 nmtc:StockOptionLiabilityMember 2018-10-01 2019-03-31 0001500198 nmtc:TwoZeroOneSevenPlanMember 2020-03-31 0001500198 nmtc:TwoZeroOneSevenPlanMember 2019-09-30 0001500198 2020-01-01 2020-03-31 0001500198 2019-11-01 0001500198 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001500198 us-gaap:CommonStockMember 2019-12-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001500198 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001500198 us-gaap:RetainedEarningsMember 2019-12-31 0001500198 2019-10-01 2019-12-31 0001500198 2019-12-31 0001500198 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001500198 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001500198 2018-10-01 2018-12-31 0001500198 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001500198 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001500198 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001500198 us-gaap:ConvertibleNotesPayableMember 2018-10-01 2019-03-31 0001500198 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-03-31 0001500198 us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-03-31 0001500198 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001500198 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001500198 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001500198 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001500198 us-gaap:StockOptionMember 2020-01-01 2020-03-31 0001500198 us-gaap:StockOptionMember 2019-01-01 2019-03-31 0001500198 nmtc:StockOptionLiabilityMember nmtc:ConsultantMember 2020-02-01 2020-02-29 0001500198 nmtc:StockOptionLiabilityMember nmtc:ConsultantOneMember 2020-02-01 2020-02-29 0001500198 nmtc:TwoZeroOneSevenPlanMember 2020-01-01 2020-03-31 0001500198 nmtc:TwoZeroOneSevenPlanMember 2019-01-01 2019-03-31 0001500198 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001500198 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001500198 nmtc:StockOptionLiabilityMember 2020-01-01 2020-03-31 0001500198 nmtc:StockOptionLiabilityMember 2019-01-01 2019-03-31 0001500198 nmtc:TwoThousandNineteenPrivatePlacementMember 2019-01-01 2019-03-31 0001500198 nmtc:TwoThousandEighteenPrivatePlacementMember 2019-01-01 2019-03-31 0001500198 nmtc:TwoThousandNineteenPrivatePlacementMember 2019-03-31 0001500198 nmtc:SecondPaulsonAmendmentMember us-gaap:SubsequentEventMember 2020-04-02 2020-04-24 0001500198 nmtc:PaulsonPrivatePlacement2020Member us-gaap:SubsequentEventMember 2020-04-30 0001500198 nmtc:PaulsonPrivatePlacement2020Member us-gaap:SubsequentEventMember 2020-04-03 2020-04-30 0001500198 nmtc:PaulsonWarrant2020Member 2020-03-31 0001500198 nmtc:PaulsonWarrant2020Member 2019-10-01 2020-03-31 0001500198 nmtc:BrokerWarrantsMember 2020-03-31 0001500198 nmtc:PayrollProtectionProgramMember 2020-03-31 0001500198 nmtc:PayrollProtectionProgramMember 2019-10-01 2020-03-31 0001500198 nmtc:SecondPaulsonAmendmentMember us-gaap:SubsequentEventMember 2020-04-15 2020-04-24 0001500198 nmtc:Paulson2019NotesMember us-gaap:SubsequentEventMember 2020-04-26 2020-05-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure nmtc:Agreements

18568

839179

2054245

0.08

0.13

817155

P12Y

P13Y

13260

260749

2305399

747244

-4395892

9657

6052161

-10457710

-1237578

10037

6842465

-11810534

-4958032

13494

15987799

-17238871

12945

14454110

-14022424

444631

-5185183

14023

18022373

-23221579

13737

17249868

-21875937

-4612332

9656505

10036505

13493705

12944514

14022423

13735874

0.001

10000000

0.001

100000000

13493705

14022423

13493705

14022423

5311

10622

11158

5579

6326

16133

58352

101076

1895

56457

99181

16154122.

532615

1389227

-17238871

-23221579

15987799

18022373

13494

14023

1770193

6574410

284235

1770193

6290175

4921076

617721

291874

1152472

1077225

532615

1389227

52026

84943

178838

167680

308055

301751

828549

41002

81305

-116809 -129763 -93858 -31716 31716 -31716 -31716 -31716 189197 1119458 335119

339157

P5Y

38462

77884

79832

81827

83873

42454

404332

-65175 4763 228709 50400 50400 171087 126001

167525

60551

4921076

93858 308395 111195

8389987

1355512

59090

1648287

6448613

600209

497244 2

P3Y

P7Y

P3Y

1.87

314395

289394

178838

167680

9807

5488

NEUROONE MEDICAL TECHNOLOGIES Corp false 10-Q 2020-03-31 2020 Q2 --09-30 Yes false Non-accelerated Filer true false 000-54716 Yes DE

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Paulson convertible notes, principal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,085,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         —</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Fair value adjustments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,683,840</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

152036

4921076

1540000

3234800

3000000 Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.

1.87

2022-11-01

2023-04-30

1831940

3.00

839179

2020-05-01

388176 30800 233223 6265 6689

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Equipment and furniture</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">99,181</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">56,457</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,895</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,895</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,076</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58,352</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,326</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,943</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">52,026</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

4921076

1683840 4921076 57756 259476 865567 419635

284235

54922

5066740

1921720

839

1920881

-835723

-419590

239522

239461

0.070

14289

19052

47866

25862

NOTE 2 – Going Concern   The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and has negative working capital, negative cash flows from operations, and an accumulated deficit of $23,221,579 as of March 31, 2020. The Company has not established a source of revenues to cover its operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.   The Company does not have adequate liquidity to fund its operations without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, these actions are not solely within the control of the Company. If the Company is unable to raise additional funds, or the Company's anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company's operations. If management is unable to obtain the necessary capital, it may have to cease operations.

Management's Use of Estimates   The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk   Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company's cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2020, the Company did have deposits in excess of federally insured amounts by $497,244.

Common Stock Valuation   The Company has been utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company's common stock since September 30, 2019. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants' Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the "AICPA Valuation Framework"). The valuation methodology included estimates and assumptions that required the Company's judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates.   The fair value the Company's common stock is used as an input into the fair value determination of instruments recorded at fair value and stock option or other equity awards that the Company has issued. Intellectual Property   The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.

Property and Equipment   Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.

Impairment of Long-Lived Assets   The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.

Debt Issuance Costs   Debt issuance costs are recorded as a reduction of the convertible promissory notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed statements of operations.

Research and Development Costs   Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (ASC) 730, Research and Development. Lastly, de minimis income from the sale of prototype products and related materials is offset against research and development expenses.

Warrant Liability   The Company issued warrants to purchase equity securities in connection with the issuance or amendment of the convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders' (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the condensed statements of operations. Premium Debt Conversion Derivatives   The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.  The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of operations.

Income Taxes   For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

Net Loss Per Share   For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.   Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's convertible promissory notes, warrants, stock options and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and six month periods ended March 31, 2020 and 2019.     The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and six month periods ended March 31, 2020 and 2019:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,389,987</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6,448,613</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,355,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,090</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,648,287</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Convertible Notes</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,921,076</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,921,076</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Convertible notes</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of beginning of period – September 30, 2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 88%; text-align: left">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,066,740</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of convertible promissory notes to common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239,522</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,858</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Warrant liability</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance as of beginning of period – September 30, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">817,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,568</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Reclassification to equity upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(835,723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Premium debt conversion derivatives</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance as of beginning of period – September 30, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,395</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of premium debt conversion derivatives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,195</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Reclassification to equity upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419,590</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Cash paid for amounts included in the measurement of lease liability:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of -use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Operating leases</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">335,119</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt">Right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">308,055</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">339,157</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted average remaining lease term (years)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5.0</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Weighted average discount rate</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">2020 (period from April 1, 2020 to September 30, 2020)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,462</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,884</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,832</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,827</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,873</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,454</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">404,332</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">339,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Short-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Long-term portion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">284,235</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

-239522

P65M

50000 100000 150000

-2211890

-3564714

-5982708

-1345642

-2211890

-3564714

-5982708

-1345642

-553447

-20534

-284557

-2697507

-1521100

-2596947

-3191343

-1377358

1521100

2596947

3191343

1377358

436311

645479

843921

342102

1084789

1951468

2347422

1035256

-0.20

-0.34

-0.43

-0.10

10971425

10360696

13780509

13904429

1743979 330000 3166384 1744 3164640 330 601319 601649 1193564 1193564 223351 223351 -698777 -698777 -149316 -149316

90000

50000

61000

153581

124503

124593

114950

115000

153520

-2211890

-1345642

-4637066

-1352824

-1345642

839179

60847

1921720

30085 30085 16569 16569

93555

42525

3273

3179

1488

1446

231296 416333 231 416102 -14022424

141666

142

254858

255000

419635

88806

463084

88806

10503 122177 289394 11 -11 122 289272

-2576280

-2475078

-104578

-383855

74574

40303

-4038 4038

-865567

129763 93858

233224

51333 1831940

10622

20965

-65000

-40224

65000

40224

2292139

486495

4933419

3001797

-617134 -72315

299000

3273 1488 1416915 3768032 255000

245000

417176

3234800

335119 2500 419635 230959 28756 835723 419590 1678361

154144

100269

(i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the 2019 Qualified Financing or (B) the ten day VWAP of the common stock prior to the first closing of a 2019 Qualified Financing. If a change of control transaction occurs prior to a 2019 Qualified Financing or the maturity date, the 2019 Paulson Notes would become payable on demand as of the closing date of such transaction 93858 93858 93858 93858 (i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">General and administrative</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">495,690</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,105</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,059,458</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">141,105</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,091</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48,092</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total share-based compensation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">531,781</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">70,217</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,119,458</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">189,197</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March  31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">    2019</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid">    2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Expected stock price volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">54.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">50.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">52.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">50.2</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.7</td><td style="text-align: left">%</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Weighted Average</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Weighted Average</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Warrants</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Per Warrant</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Term (years)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%">Outstanding and exercisable at September 30, 2019</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">7,265,598</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">1.80 - 3.00</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">2.55</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">3.60</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Issued</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,124,389</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.87</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.87</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4.26</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Forfeited</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Outstanding and exercisable at March 31, 2020</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,389,987</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.80 - 3.00</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2.45</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.26</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td></tr></table>

1.00

The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through March 31, 2020.

1.00

P6Y

4359

70217

189197

1119458

1059458

141105

60000

48092

531781

495690

26105

36091

44112

0.528

0.502

0.543

0.507

P5Y8M12D

P5Y10M25D

P5Y4M24D

P6Y0M0D

0.00

0.017

0.027

0.014

0.026

250000

1.06 1.12 2.00 2.65 1.15 1.11

27543

278175

526888

46654

23563

88806

46654

153581

115000

90000

36000

422694

39675

133272

60000

50000

46865

39675

122767

115000 0

820000

325548

167851

20000

150548

167851

800000

P2Y10M25D

2.30 2063506

267803

260306

7003

1355512

845840

0.00

7265598 8389987 1124389

1.80 3.00 1.87 1.80 3.00 2.55 1.87 2.45 P4Y3M4D P3Y3M4D (i) 1 share (each, a “Share”) of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”). The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. (i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”), to the New Purchasers. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Unit Private Placement.

2.50

173067

1150359

35665

812428

722806

-24029

1.80 170000 1903979 1743979 0 1538000 5845448 255000

The SEC covering the resale of the shares of common stock sold in the private placement within 60 days of the termination of the private placement.

615200 2338179 141666 1000000 0.13

1854800

The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the "2020 Qualified Financing"), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the "Outstanding Balance") shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.

The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $3,000,000 or a higher amount determined by the Board.

If the Company announces a transaction between the Company and any other company (or an affiliate of any such company) that is included in the S&P 500 Health Care Index as published from time to time by S&P Dow Jones Indices LLC that includes an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration, manufacturing, distribution, licensing or supply of the Company's products (a "Strategic Transaction") before the maturity date, without any action on the part of the subscribers, the Outstanding Balance shall be converted into that number of shares of common stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the Company of a Strategic Transaction. 0.50 Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction. 0.12 0.15

P2Y0M0D

-416333

P5Y The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding. 0001500198

NOTE 1 – Description of Business and Basis of Presentation   NeuroOne Medical Technologies Corporation (the "Company"), a Delaware Corporation, is an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson's disease, essential tremors, and other brain related disorders.   To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology. The Company received clearance to market the initial device and expect to submit for additional clearance for a second product by end of year. The Company is also evaluating different options for commercializing the current approved device.   The Company is based in Eden Prairie, Minnesota.   COVID-19   On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus ("COVID-19") as a global pandemic, which continues to spread throughout the United States and around the world. As a result of the COVID-19 pandemic, the Company has experienced delays and disruptions in its pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, and research and development operations. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic may impact our business and pre-clinical and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic may also impact the Company's ability to secure additional financing or its ability to up-list from its current OTC Market ("OTCQB"), and may result in further modifications to its debt agreements. See NOTE 12 – Subsequent Events. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company's results of future operations, financial position, and liquidity in fiscal year 2020.   Basis of presentation   The accompanying condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended September 30, 2019 included in the Annual Report on Form 10-K. The condensed balance sheet at September 30, 2019 was derived from the audited financial statements of the Company.   In December 2019, the Company merged its wholly owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the Company's wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company did not have any remaining entities that required consolidation for financial statement reporting purposes.   In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.

NOTE 3 – Summary of Significant Accounting Policies   Management’s Use of Estimates   The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company’s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2020, the Company did have deposits in excess of federally insured amounts by $497,244.   Common Stock Valuation   The Company has been utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company’s common stock since September 30, 2019. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the “AICPA Valuation Framework”). The valuation methodology included estimates and assumptions that required the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates.   The fair value the Company’s common stock is used as an input into the fair value determination of instruments recorded at fair value and stock option or other equity awards that the Company has issued.     Fair Value of Financial Instruments   The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</td></tr> </table>   As of March 31, 2020 and September 30, 2019, the fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the convertible notes outstanding during the three and six month period ended March 31, 2020 were based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.   The estimated fair value of the convertible promissory notes of the Company that were outstanding during the three and six month period ended March 31, 2019 were based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes outstanding during fiscal 2019 were based on both the estimated fair value of our common stock and cash flow models discounted at the then current implied market rates evidenced in arms-length transactions representing expected returns by market participants for similar instruments during that period and were based on Level 3 inputs.   There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019.   The fair value of financial instruments measured on a recurring basis is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Convertible Notes</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,921,076</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,921,076</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The following table provides a roll-forward of the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the six month periods ended March 31 as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Convertible notes</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of beginning of period – September 30, 2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 88%; text-align: left">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,066,740</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of convertible promissory notes to common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239,522</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,858</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Warrant liability</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance as of beginning of period – September 30, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">817,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,568</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Reclassification to equity upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(835,723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>     <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Premium debt conversion derivatives</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance as of beginning of period – September 30, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,395</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of premium debt conversion derivatives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,195</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Reclassification to equity upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419,590</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Intellectual Property   The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.   Property and Equipment   Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.   Impairment of Long-Lived Assets   The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.   Debt Issuance Costs   Debt issuance costs are recorded as a reduction of the convertible promissory notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed statements of operations.     Research and Development Costs   Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (ASC) 730, Research and Development. Lastly, de minimis income from the sale of prototype products and related materials is offset against research and development expenses.   Warrant Liability   The Company issued warrants to purchase equity securities in connection with the issuance or amendment of the convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders’ (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the condensed statements of operations.     Premium Debt Conversion Derivatives   The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.  The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of operations based on the fair value of its common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.    Income Taxes   For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.   Net Loss Per Share   For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.   Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company’s convertible promissory notes, warrants, stock options and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and six month periods ended March 31, 2020 and 2019.     The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and six month periods ended March 31, 2020 and 2019:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">8,389,987</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6,448,613</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,355,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600,209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,090</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,648,287</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> </table>   Recent Accounting Pronouncements   In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company adopted the new standard on October 1, 2019 and did not have a material impact on the Company’s statements of comprehensive loss or statements of cash flows for agreements in place as of the adoption date. As such, the Company did not restate comparative periods and did not recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company elected the short-term lease expedient upon adoption of the standard. See NOTE 4 – Commitments and Contingencies with regard to a new operating lease that commenced after the adoption date on November 1, 2019.   In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December 15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new guidance on October 1, 2019, and the new guidance did not have an impact on the Company’s financial statements as of the adoption date.   In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13). The new guidance modifies the disclosure requirements in Topic 820 as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.</td></tr> </table>   This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance and does not expect that it will have a material impact on its financial statements.   In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial statements.

Fair Value of Financial Instruments   The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</td></tr> </table>   As of March 31, 2020 and September 30, 2019, the fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the convertible notes outstanding during the three and six month period ended March 31, 2020 were based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.   The estimated fair value of the convertible promissory notes of the Company that were outstanding during the three and six month period ended March 31, 2019 were based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes outstanding during fiscal 2019 were based on both the estimated fair value of our common stock and cash flow models discounted at the then current implied market rates evidenced in arms-length transactions representing expected returns by market participants for similar instruments during that period and were based on Level 3 inputs.   There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019.   The fair value of financial instruments measured on a recurring basis is as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 1.5pt">Convertible Notes</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,921,076</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,921,076</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total liabilities at fair value</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The following table provides a roll-forward of the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the six month periods ended March 31 as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Convertible notes</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of beginning of period – September 30, 2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 88%; text-align: left">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,066,740</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of convertible promissory notes to common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239,522</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,858</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,921,076</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Warrant liability</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance as of beginning of period – September 30, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">817,155</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of warrant liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,568</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Reclassification to equity upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(835,723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Premium debt conversion derivatives</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Balance as of beginning of period – September 30, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">308,395</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of premium debt conversion derivatives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,195</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Reclassification to equity upon conversion of convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419,590</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of end of period – March 31, 2019</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">—</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

Recent Accounting Pronouncements   In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company adopted the new standard on October 1, 2019 and did not have a material impact on the Company’s statements of comprehensive loss or statements of cash flows for agreements in place as of the adoption date. As such, the Company did not restate comparative periods and did not recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company elected the short-term lease expedient upon adoption of the standard. See NOTE 4 – Commitments and Contingencies with regard to a new operating lease that commenced after the adoption date on November 1, 2019.   In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December 15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new guidance on October 1, 2019, and the new guidance did not have an impact on the Company’s financial statements as of the adoption date.   In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13). The new guidance modifies the disclosure requirements in Topic 820 as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.</td></tr> </table>   This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance and does not expect that it will have a material impact on its financial statements.   In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial statements.

NOTE 12 – Subsequent Events   Amendment of 2019 Paulson Notes   On April 24, 2020, the Company and holders of a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the "Second Paulson Amendment") to, among other things:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">i.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Extend the Maturity Date – The Second Paulson Amendment extends the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either case, unless a change of control transaction happens prior to such date);</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">ii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revise Optional Conversion Terms – The Second Paulson Amendment provides that the amount of shares to be received upon the a subscriber's optional conversion of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) will be equal to: (1) the Outstanding Balance of such subscriber's 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion; and</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">iii.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revise the Registration Date – The Second Paulson Amendment provides that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber has converted all or a majority of the Outstanding Balance of such subscriber's 2019 Paulson Note prior to such date; (2) the final closing a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.</td></tr> </table>   There were no other significant changes to terms under the Second Paulson Amendment.   2019 Paulson Note Conversion   Between April 24, 2020 and May 1, 2020, certain holders elected to convert outstanding principal and accrued and unpaid interest of 2019 Paulson Notes in the amount of $2,633,280 into 2,054,245 shares of common stock.   Paulson 2020 Convertible Note Financing    On April 30, 2020, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the "2020 Paulson Private Placement"), agreed to issue and sell to the investors up to $3 million of 13% convertible promissory notes (each, a "2020 Paulson Note" and collectively, the "2020 Paulson Notes") and warrants (each, a "2020 Paulson Warrant" and collectively, the "2020 Paulson Warrants") to purchase shares of the Company's common stock.    Between April 30, 2020 and May 8, 2020, the Company issued 2020 Paulson Notes in an aggregate principal amount of $2,469,800 to the Subscribers. The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $6,000,000 or a higher amount determined by the Board.   The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the "2020 Qualified Financing"), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the "Outstanding Balance") shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.   If the Company announces a transaction between the Company and any other company (or an affiliate of any such company) that is included in the S&P 500 Health Care Index as published from time to time by S&P Dow Jones Indices LLC that includes an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration, manufacturing, distribution, licensing or supply of the Company's products (a "Strategic Transaction") before the maturity date, without any action on the part of the subscribers, the Outstanding Balance shall be converted into that number of shares of common stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the Company of a Strategic Transaction.   At any time, at the sole election of the holder of such 2020 Paulson Note, all or a portion of the Outstanding Balance may be converted into that number of shares of common stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.   If a change of control transaction occurs prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.   Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction.   In connection with the 2020 Paulson Private Placement, Paulson will receive a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes, and at the final closing of the 2020 Paulson Private Placement, Paulson will receive 7-year warrants to purchase an amount of common stock equal to 15% of the total gross proceeds received by the Company in the 2020 Paulson Private Placement, divided by 1.87 (the "Broker Warrants"). The Broker Warrants will have an exercise price equal to $1.87.   2020 Paulson Note Conversions   Between May 4, 2020 and May 12, 2020, certain Subscribers elected to convert $50,153 of the outstanding principal and interest of such Subscribers' 2020 Paulson Notes into 38,335 shares of common stock.   Payroll Protection Program   The CARES Act, signed into law in March 2020, established the Paycheck Protection Program ("PPP"). The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments may be made without penalty. In April 2020, the Company received loan funding of approximately $83,333 under the PPP.   Amendment to Veritas Consulting Agreement   On April 22, 2020, the Company entered into an amendment (the "Amendment") to the Consulting Agreement, by and between the Company and Veritas Consulting Group Inc. ("Veritas"). Pursuant to the Amendment, the Company issued Veritas an additional 35,000 shares in exchange for consulting services.    PMT Litigation   On April 29, 2020, the district court granted the Company's motion for sanctions. Additionally, the district court granted the Company's motion for summary judgment in part with respect to the counts for Christianson's breach of non-confidentiality agreement, Fredrickson's breach of confidentiality covenants, and the creation of a constructive trust and denied the Company's motion for summary judgment on all other counts.

3085200 60847 864913 P3Y7M6D 555555 0.01 83333 2020-05-01 2020-11-01 3000000

2633280

P4Y9M18D

EX-101.SCH 5 nmtc-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Intangibles and Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Convertible Promissory Notes and Warrant Agreements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangibles and Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Summary of Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments and Contingencies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Commitments and Contingencies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Intangibles and Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Intangibles and Property and Equipment (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Intangibles and Property and Equipment (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Defined Contribution Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Stockholders' Deficit (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nmtc-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 nmtc-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 nmtc-20200331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Warrant [Member] Debt Instrument [Axis] Debt Conversion Derivative [Member] Short-term Debt, Type [Axis] Convertible Promissory Note [Member] Sale of Stock [Axis] 2018 Private Placement [Member] Derivative Instrument [Axis] Stock- option liability [Member] Convertible Debt One [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Range [Axis] Minimum [Member] Maximum [Member] Convertible Notes [Member] Antidilutive Securities [Axis] Employee Stock Option [Member] Restricted Stock Units [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Software [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Research and Development Expense [Member] Equity Option [Member] Plan Name [Axis] 2017 Plan [Member] Two Thousand Sixteen And Seventeen Plan [Member] Award Type [Axis] Restricted Stock [Member] Title of Individual [Axis] Consultant [Member] Consultant One [Member] 2019 Private Placement [Member] Convertible Notes [Member] Related Party [Axis] Paulson Private Placement [Member] Second Paulson Amendment [Member] Subsequent Event Type [Axis] Subsequent Event [Member] 2020 Paulson Private Placement [Member] 2020 Paulson Warrant [Member] Broker Warrants [Member] Payroll Protection Program [Member] 2019 Paulson Notes [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity File Number Entity Interactive Data Current Entity Incorporation State Country Code Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets Current assets: Cash Prepaid and other assets Total current assets Right-of-use asset Intangible assets, net Property and equipment, net Total assets Liabilities and Stockholders' Deficit Current liabilities: Accounts payable Accrued expenses Convertible promissory notes (Note 7) Total current liabilities Lease liability Total liabilities Commitments and contingencies (Note 4) Stockholders' deficit: Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2020 and September 30, 2019; no shares issued or outstanding as of March 31, 2020 and September 30, 2019. Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and September 30, 2019; 14,022,423 and 13,493,705 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively. Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: General and administrative Research and development Total operating expenses Loss from operations Interest expense Net valuation change of instruments measured at fair value Loss on notes extinguishment Loss before income taxes Provision for income taxes Net loss Net loss per share: Basic and diluted Number of shares used in per share calculations: Basic and diluted Statement [Table] Statement [Line Items] Common Stock Additional Paid-In Capital Accumulated Deficit Balance Balance, shares Issuance of common stock under securities purchase agreement Issuance of common stock under securities purchase agreement, shares Issuance cost attributed to securities purchase agreement Issuance of warrants in connection with convertible notes offering Stock-based compensation Issuance of common stock under private placement Issuance of common stock under private placements, shares Issuance of warrants under private placements Issuance costs related to private placements Issuance of common stock upon conversion of convertible promissory notes Issuance of common stock upon conversion of convertible promissory notes, shares Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes, shares Share-based compensation - employee Share-based compensation - non-employee Exercise of stock options Exercise of stock options, shares Exercise of warrants Exercise of warrants, shares Issuance of common stock for consulting services Issuance of common stock for consulting services, shares Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Amortization and depreciation Stock-based compensation Non-cash interest on convertible notes Non-cash discount amortization on convertible notes Revaluation of convertible notes Revaluation of premium conversion derivatives and warrant liability Issuance costs attributed to financing activities Loss on notes extinguishment Lease liability principal payment deferral Right-of-use asset depreciation adjustment Change in assets and liabilities: Prepaid and other assets Accounts payable and other accrued liabilities Net cash used in operating activities Investing activities Purchase of fixed assets and intangible assets Net cash used in investing activities Financing activities Proceeds from issuance of convertible promissory notes Issuance costs related to convertible notes Proceeds from unsecured loans Proceeds from issuance of common stock in connection with private placements Proceeds from issuance of warrants in connection with private placements Exercise of warrants Exercise of stock options Repayment of unsecured loans Issuance costs related to private placements Net cash provided by financing activities Net increase in cash Cash at beginning of period Cash at end of period Supplemental non-cash financing and investing transactions: Conversion of convertible promissory notes to equity Exercise of premium conversion derivative liability Reclassification of warrant liability to equity Unpaid issuance costs attributed to convertible notes and private placement Broker warrants issued in connection with convertible notes Purchased fixed assets in accounts payable and accrued expenses Operating lease right of use asset obtained in exchange for operating lease EX-101.PRE 9 nmtc-20200331_pre.xml XBRL PRESENTATION FILE XML 10 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details)	Mar. 31, 2020 USD ($)
Liabilities:
Convertible Notes	$ 4,921,076
Total liabilities at fair value	4,921,076
Level 1 [Member]
Liabilities:
Convertible Notes
Total liabilities at fair value
Level 2 [Member]
Liabilities:
Convertible Notes
Total liabilities at fair value
Level 3 [Member]
Liabilities:
Convertible Notes	4,921,076
Total liabilities at fair value	$ 4,921,076

XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 146 385 1 false 39 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://originalsourcemusic.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://originalsourcemusic.com/role/ConsolidatedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://originalsourcemusic.com/role/ConsolidatedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://originalsourcemusic.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://originalsourcemusic.com/role/StatementsOfChangesInStockholdersDeficit Condensed Statements of Changes in Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://originalsourcemusic.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Description of Business and Basis of Presentation Sheet http://originalsourcemusic.com/role/DescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://originalsourcemusic.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Commitments and Contingencies Sheet http://originalsourcemusic.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 10 false false R11.htm 00000011 - Disclosure - Intangibles and Property and Equipment Sheet http://originalsourcemusic.com/role/Intangibles Intangibles and Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Accrued Expenses Sheet http://originalsourcemusic.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 00000013 - Disclosure - Convertible Promissory Notes and Warrant Agreements Notes http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements Convertible Promissory Notes and Warrant Agreements Notes 13 false false R14.htm 00000014 - Disclosure - Defined Contribution Plan Sheet http://originalsourcemusic.com/role/DefinedContributionPlan Defined Contribution Plan Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Compensation Sheet http://originalsourcemusic.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://originalsourcemusic.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Stockholders' Deficit Sheet http://originalsourcemusic.com/role/StockholdersDeficit Stockholders' Deficit Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://originalsourcemusic.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies (Tables) Sheet http://originalsourcemusic.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://originalsourcemusic.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - Intangibles and Property and Equipment (Tables) Sheet http://originalsourcemusic.com/role/IntangiblesTables Intangibles and Property and Equipment (Tables) Tables http://originalsourcemusic.com/role/Intangibles 22 false false R23.htm 00000023 - Disclosure - Accrued Expenses (Tables) Sheet http://originalsourcemusic.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://originalsourcemusic.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables) Notes http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsTables Convertible Promissory Notes and Warrant Agreements (Tables) Tables http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements 24 false false R25.htm 00000025 - Disclosure - Stock-Based Compensation (Tables) Sheet http://originalsourcemusic.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://originalsourcemusic.com/role/StockBasedCompensation 25 false false R26.htm 00000026 - Disclosure - Stockholders' Deficit (Tables) Sheet http://originalsourcemusic.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://originalsourcemusic.com/role/StockholdersDeficit 26 false false R27.htm 00000027 - Disclosure - Going Concern (Details) Sheet http://originalsourcemusic.com/role/GoingConcernDetails Going Concern (Details) Details http://originalsourcemusic.com/role/GoingConcern 27 false false R28.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - Summary of Significant Accounting Policies (Details 2) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details 2) Details http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - Summary of Significant Accounting Policies (Details 3) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetails3 Summary of Significant Accounting Policies (Details 3) Details http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - Summary of Significant Accounting Policies (Details 4) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetails4 Summary of Significant Accounting Policies (Details 4) Details http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - Commitments and Contingencies (Details) Sheet http://originalsourcemusic.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://originalsourcemusic.com/role/CommitmentsAndContingenciesTables 34 false false R35.htm 00000035 - Disclosure - Commitments and Contingencies (Details 1) Sheet http://originalsourcemusic.com/role/CommitmentsAndContingenciesDetails1 Commitments and Contingencies (Details 1) Details http://originalsourcemusic.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - Commitments and Contingencies (Details 2) Sheet http://originalsourcemusic.com/role/CommitmentsAndContingenciesDetails2 Commitments and Contingencies (Details 2) Details http://originalsourcemusic.com/role/CommitmentsAndContingenciesTables 36 false false R37.htm 00000037 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://originalsourcemusic.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://originalsourcemusic.com/role/CommitmentsAndContingenciesTables 37 false false R38.htm 00000038 - Disclosure - Intangibles and Property and Equipment (Details) Sheet http://originalsourcemusic.com/role/IntangiblesDetails Intangibles and Property and Equipment (Details) Details http://originalsourcemusic.com/role/IntangiblesTables 38 false false R39.htm 00000039 - Disclosure - Intangibles and Property and Equipment (Details 1) Sheet http://originalsourcemusic.com/role/IntangiblesDetails1 Intangibles and Property and Equipment (Details 1) Details http://originalsourcemusic.com/role/IntangiblesTables 39 false false R40.htm 00000040 - Disclosure - Intangibles and Property and Equipment (Details Textual) Sheet http://originalsourcemusic.com/role/IntangiblesAndPropertyAndEquipmentDetailsTextual Intangibles and Property and Equipment (Details Textual) Details http://originalsourcemusic.com/role/IntangiblesTables 40 false false R41.htm 00000041 - Disclosure - Accrued Expenses (Details) Sheet http://originalsourcemusic.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://originalsourcemusic.com/role/AccruedExpensesTables 41 false false R42.htm 00000042 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details) Notes http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetails Convertible Promissory Notes and Warrant Agreements (Details) Details http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsTables 42 false false R43.htm 00000043 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details Textual) Notes http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsDetailsTextual Convertible Promissory Notes and Warrant Agreements (Details Textual) Details http://originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreementsTables 43 false false R44.htm 00000044 - Disclosure - Defined Contribution Plan (Details) Sheet http://originalsourcemusic.com/role/DefinedContributionPlanDetails Defined Contribution Plan (Details) Details http://originalsourcemusic.com/role/DefinedContributionPlan 44 false false R45.htm 00000045 - Disclosure - Stock-Based Compensation (Details) Sheet http://originalsourcemusic.com/role/Stock-basedCompensationDetails Stock-Based Compensation (Details) Details http://originalsourcemusic.com/role/Stock-basedCompensationTables 45 false false R46.htm 00000046 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://originalsourcemusic.com/role/Stock-basedCompensationDetails1 Stock-Based Compensation (Details 1) Details http://originalsourcemusic.com/role/Stock-basedCompensationTables 46 false false R47.htm 00000047 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://originalsourcemusic.com/role/Stock-basedCompensationDetailsTextual Stock-Based Compensation (Details Textual) Details http://originalsourcemusic.com/role/Stock-basedCompensationTables 47 false false R48.htm 00000048 - Disclosure - Income Taxes (Details) Sheet http://originalsourcemusic.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://originalsourcemusic.com/role/IncomeTaxes 48 false false R49.htm 00000049 - Disclosure - Stockholders' Deficit (Details) Sheet http://originalsourcemusic.com/role/StockholdersDeficitDetails Stockholders' Deficit (Details) Details http://originalsourcemusic.com/role/StockholdersDeficitTables 49 false false R50.htm 00000050 - Disclosure - Stockholders' Deficit (Details Textual) Sheet http://originalsourcemusic.com/role/StockholdersDeficitDetailsTextual Stockholders' Deficit (Details Textual) Details http://originalsourcemusic.com/role/StockholdersDeficitTables 50 false false R51.htm 00000051 - Disclosure - Subsequent Events (Details) Sheet http://originalsourcemusic.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://originalsourcemusic.com/role/SubsequentEvents 51 false false All Reports Book All Reports nmtc-20200331.xml nmtc-20200331.xsd nmtc-20200331_cal.xml nmtc-20200331_def.xml nmtc-20200331_lab.xml nmtc-20200331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 12 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Schedule of fair value of financial instruments measured on a recurring basis

	As of March 31, 2020
Description	Total		Level 1		Level 2		Level 3
Liabilities:
Convertible Notes	$	4,921,076		—		—	$	4,921,076
Total liabilities at fair value	$	4,921,076		—		—	$	4,921,076

Schedule of convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis

	2020
Convertible notes
Balance as of beginning of period – September 30, 2019	$	—
Fair value attributed to convertible promissory notes upon issuance		5,066,740
Conversion of convertible promissory notes to common stock		(239,522	)
Change in fair value including accrued interest		93,858
Balance as of end of period – March 31, 2020	$	4,921,076

	2019
Warrant liability
Balance as of beginning of period – September 30, 2018	$	817,155
Change in fair value of warrant liability		18,568
Reclassification to equity upon conversion of convertible promissory notes		(835,723	)
Balance as of end of period – March 31, 2019	$	—

	2019
Premium debt conversion derivatives
Balance as of beginning of period – September 30, 2018	$	308,395
Change in fair value of premium debt conversion derivatives		111,195
Reclassification to equity upon conversion of convertible promissory notes		(419,590	)
Balance as of end of period – March 31, 2019	$	—

Schedule of computation of diluted net loss per share

	2020		2019
Warrants		8,389,987		6,448,613
Stock options		1,355,512		600,209
Restricted stock units		59,090		—
Convertible notes		1,648,287		—

XML 13 R24.htm IDEA: XBRL DOCUMENT

Convertible Promissory Notes and Warrant Agreements (Tables)

6 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Schedule of convertible promissory notes and warrant agreements

	As of March 31, 2020		As of September 30, 2019
Paulson convertible notes, principal	$	3,085,200	$	—
Accrued interest		152,036		—
Fair value adjustments		1,683,840		—
	$	4,921,076	$	—

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2018	$ 9,657	$ 6,052,161	$ (10,457,710)	$ (4,395,892)
Balance, shares at Sep. 30, 2018	9,656,505
Issuance of common stock under private placement	$ 330	601,319		601,649
Issuance of common stock under private placements, shares	330,000
Issuance of warrants under private placements		223,351		223,351
Issuance costs related to private placements		(149,316)		(149,316)
Issuance of common stock for consulting services	$ 50	114,950		115,000
Issuance of common stock for consulting services, shares	50,000
Net loss			(1,352,824)	(1,352,824)
Balance at Dec. 31, 2018	$ 10,037	6,842,465	(11,810,534)	(4,958,032)
Balance, shares at Dec. 31, 2018	10,036,505
Balance at Sep. 30, 2018	$ 9,657	6,052,161	(10,457,710)	(4,395,892)
Balance, shares at Sep. 30, 2018	9,656,505
Balance at Mar. 31, 2019	$ 12,945	14,454,110	(14,022,424)	444,631
Balance, shares at Mar. 31, 2019	12,944,514
Balance at Dec. 31, 2018	$ 10,037	6,842,465	(11,810,534)	(4,958,032)
Balance, shares at Dec. 31, 2018	10,036,505
Issuance of common stock under private placement	$ 1,744	3,164,640		3,166,384
Issuance of common stock under private placements, shares	1,743,979
Issuance of warrants under private placements		1,193,564		1,193,564
Issuance costs related to private placements		(698,777)		(698,777)
Issuance of common stock upon conversion of convertible promissory notes	$ 839	1,920,881		1,921,720
Issuance of common stock upon conversion of convertible promissory notes, shares	839,179
Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes		1,921,720		1,921,720
Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes, shares
Share-based compensation - employee		30,085		30,085
Share-based compensation - non-employee		16,569		16,569
Exercise of stock options	$ 94	3,179		3,273
Exercise of stock options, shares	93,555
Exercise of warrants	$ 231	416,102	(14,022,424)	416,333
Exercise of warrants, shares	231,296
Net loss			(2,211,890)	(2,211,890)
Balance at Mar. 31, 2019	$ 12,945	14,454,110	(14,022,424)	444,631
Balance, shares at Mar. 31, 2019	12,944,514
Balance at Sep. 30, 2019	$ 13,494	15,987,799	(17,238,871)	(1,237,578)
Balance, shares at Sep. 30, 2019	13,493,705
Issuance of common stock under securities purchase agreement	$ 142	254,858		255,000
Issuance of common stock under securities purchase agreement, shares	141,666
Issuance of warrants in connection with convertible notes offering		419,635		419,635
Stock-based compensation		463,084		463,084
Issuance of common stock for consulting services	$ 90	124,503		124,593
Issuance of common stock for consulting services, shares	90,000
Issuance of common stock upon vesting of restricted stock units	$ 11	(11)
Issuance of common stock upon vesting of restricted stock units, shares	10,503
Net loss			(4,637,066)	(4,637,066)
Balance at Dec. 31, 2019	$ 13,737	17,249,868	(21,875,937)	(4,612,332)
Balance, shares at Dec. 31, 2019	13,735,874
Stock-based compensation		88,806		88,806
Issuance of common stock upon conversion of convertible promissory notes	$ 61	239,461		239,522
Issuance of common stock upon conversion of convertible promissory notes, shares	60,847
Exercise of stock options	$ 42	1,446		1,488
Exercise of stock options, shares	42,525
Issuance of common stock for consulting services	$ 61	153,520		153,581
Issuance of common stock for consulting services, shares	61,000
Issuance of common stock upon vesting of restricted stock units	$ 122	289,272		289,394
Issuance of common stock upon vesting of restricted stock units, shares	122,177
Net loss			(1,345,642)	(1,345,642)
Balance at Mar. 31, 2020	$ 14,023	$ 18,022,373	$ (23,221,579)	$ (5,185,183)
Balance, shares at Mar. 31, 2020	14,022,423

XML 15 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 08, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	NEUROONE MEDICAL TECHNOLOGIES Corp
Entity Central Index Key	0001500198
Amendment Flag	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	000-54716
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity Common Stock, Shares Outstanding		161,541,22.

XML 16 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 3 – Summary of Significant Accounting Policies

Management’s Use of Estimates

Concentration of Credit Risk

Common Stock Valuation

Fair Value of Financial Instruments

●	Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

●	Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

●	Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019.

The fair value of financial instruments measured on a recurring basis is as follows:

	As of March 31, 2020
Description	Total		Level 1		Level 2		Level 3
Liabilities:
Convertible Notes	$	4,921,076		—		—	$	4,921,076
Total liabilities at fair value	$	4,921,076		—		—	$	4,921,076

	2020
Convertible notes
Balance as of beginning of period – September 30, 2019	$	—
Fair value attributed to convertible promissory notes upon issuance		5,066,740
Conversion of convertible promissory notes to common stock		(239,522	)
Change in fair value including accrued interest		93,858
Balance as of end of period – March 31, 2020	$	4,921,076

	2019
Warrant liability
Balance as of beginning of period – September 30, 2018	$	817,155
Change in fair value of warrant liability		18,568
Reclassification to equity upon conversion of convertible promissory notes		(835,723	)
Balance as of end of period – March 31, 2019	$	—

	2019
Premium debt conversion derivatives
Balance as of beginning of period – September 30, 2018	$	308,395
Change in fair value of premium debt conversion derivatives		111,195
Reclassification to equity upon conversion of convertible promissory notes		(419,590	)
Balance as of end of period – March 31, 2019	$	—

Intellectual Property

Property and Equipment

Impairment of Long-Lived Assets

Debt Issuance Costs

Research and Development Costs

Warrant Liability

Premium Debt Conversion Derivatives

Income Taxes

Net Loss Per Share

For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.

	2020		2019
Warrants		8,389,987		6,448,613
Stock options		1,355,512		600,209
Restricted stock units		59,090		—
Convertible notes		1,648,287		—

Recent Accounting Pronouncements

	●	Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.

	●	Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.

●

XML 17 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
Stock-Based Compensation (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 531,781	$ 70,217	$ 1,119,458	$ 189,197
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	495,690	26,105	1,059,458	141,105
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 36,091	$ 44,112	$ 60,000	$ 48,092

XML 18 R41.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Payables and Accruals [Abstract]
Legal services		$ 228,709
Accrued issuance costs	50,400	50,400
Accrued payroll	126,001	171,087
Lease liability, short-term	54,922
Other	60,551	167,525
Total accrued expenses	$ 291,874	$ 617,721

XML 19 R49.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details) - Warrant [Member]	6 Months Ended
Stockholders' Deficit (Details) - Warrant [Member]	Mar. 31, 2020 $ / shares shares
Class of Warrant or Right [Line Items]
Outstanding, Beginning \| shares	7,265,598
Issued \| shares	1,124,389
Exercised \| shares
Forfeited \| shares
Outstanding, Exercisable Ending \| shares	8,389,987
Exercise Price Per Warrant, Issued	$ 1.87
Exercise Price Per Warrant, Exercised
Exercise Price Per Warrant, Forfeited
Weighted Average Exercise Price, Beginning	2.55
Weighted Average Exercise Price, Issued	1.87
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Exercisable Ending	$ 2.45
Outstanding, Weighted Average Term (years), Beginning	3 years 7 months 6 days
Outstanding, Weighted Average Term (years), Issued	4 years 3 months 4 days
Outstanding, Weighted Average Term (years), Ending	3 years 3 months 4 days
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price Per Warrant, Beginning	$ 1.80
Exercise Price Per Warrant, Exercisable Ending	1.80
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price Per Warrant, Beginning	3.00
Exercise Price Per Warrant, Exercisable Ending	$ 3.00

XML 20 R50.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details Textual) - USD ($)			1 Months Ended		3 Months Ended	6 Months Ended
Stockholders' Deficit (Details Textual) - USD ($)	Dec. 12, 2018	Nov. 30, 2018	Oct. 23, 2019	Dec. 28, 2018	Mar. 31, 2019	Mar. 31, 2019
Warrant [Member]
Stockholders' Deficit (Textual)
Purchase price, per share			$ 1.80
Maximum shares to be issued under private placement			555,555
Gross proceeds from private placement			$ 255,000
Private placement transaction, description			The SEC covering the resale of the shares of common stock sold in the private placement within 60 days of the termination of the private placement.
Shares issued under private placement			141,666
Maximum potential gross proceeds from financing			$ 1,000,000
2018 Private Placement [Member]
Stockholders' Deficit (Textual)
Purchase agreement, description		(i) 1 share (each, a “Share”) of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”). The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing.
Offering price, per share	$ 2.50
Cost of issuance	$ 173,067				$ (24,029)	$ 35,665
Units sold under private placement					0	170,000
Gross proceeds from private placement	$ 1,538,000
Shares issued under private placement	615,200
2019 Private Placement [Member]
Stockholders' Deficit (Textual)
Purchase agreement, description				(i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”), to the New Purchasers. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Unit Private Placement.
Offering price, per share				$ 2.50	$ 2.50	$ 2.50
Cost of issuance				$ 1,150,359	$ 722,806	$ 812,428
Units sold under private placement					1,743,979	1,903,979
Gross proceeds from private placement				$ 5,845,448
Shares issued under private placement				2,338,179

XML 21 R35.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details 1) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets	$ 308,055
Lease liability	$ 339,157
Weighted average remaining lease term (years)	5 years
Weighted average discount rate	7.00%

XML 22 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 3) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reclassification to equity upon conversion of convertible promissory notes	$ 239,522	$ 1,921,720
Debt Conversion Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period – September 30, 2018			$ 308,395
Change in fair value of premium debt conversion derivatives			111,195
Reclassification to equity upon conversion of convertible promissory notes			(419,590)
Balance as of end of period – March 31, 2019

XML 23 R39.htm IDEA: XBRL DOCUMENT

Intangibles and Property and Equipment (Details 1) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Equipment and furniture	$ 99,181	$ 56,457
Software	1,895	1,895
Total property and equipment	101,076	58,352
Less accumulated depreciation	(16,133)	(6,326)
Property and equipment, net	$ 84,943	$ 52,026

XML 24 R12.htm IDEA: XBRL DOCUMENT

Accrued Expenses

6 Months Ended

Mar. 31, 2020

Payables and Accruals [Abstract]

Accrued Expenses

NOTE 6 - Accrued Expenses

Accrued expenses consisted of the following at March 31, 2020 and September 30, 2019:

	As of
	March 31, 2020		September 30, 2019
Legal services	$	—	$	228,709
Accrued issuance costs		50,400		50,400
Accrued payroll		126,001		171,087
Lease liability, short-term		54,922		—
Other		60,551		167,525
	$	291,874	$	617,721

The “other” category is primarily comprised of board fees.

XML 25 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 10 – Income Taxes

The effective tax rate for the three and six months ended March 31, 2020 and 2019 was zero percent. As a result of the analysis of all available evidence as of March 31, 2020 and September 30, 2019, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported no income tax benefit during the three and six months ended March 31, 2020 and 2019. If the Company's assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense. If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets. However, the Company is continuing to assess the impact of the CARES Act.

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") which includes modifications to the limitation on business interest expense and net operating loss provisions, and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. The CARES Act is not expected to have a material impact on the Company's financial statements.

XML 26 R51.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)			1 Months Ended		6 Months Ended
Subsequent Events (Details) - USD ($)	May 01, 2020	Apr. 24, 2020	Apr. 30, 2020	Apr. 24, 2020	Mar. 31, 2020
Subsequent Events (Textual)
Paycheck protection program, description					The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding.
Convertible note, description					The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the "2020 Qualified Financing"), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the "Outstanding Balance") shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.
Affiliate company, description					If the Company announces a transaction between the Company and any other company (or an affiliate of any such company) that is included in the S&P 500 Health Care Index as published from time to time by S&P Dow Jones Indices LLC that includes an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration, manufacturing, distribution, licensing or supply of the Company's products (a "Strategic Transaction") before the maturity date, without any action on the part of the subscribers, the Outstanding Balance shall be converted into that number of shares of common stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the Company of a Strategic Transaction.
Outstanding voting power, percentage					50.00%
Second Paulson Amendment [Member] \| Subsequent Event [Member]
Subsequent Events (Textual)
Original maturity date				May 01, 2020
Amended maturity date				Nov. 01, 2020
Notes converted amount		$ 2,633,280
2019 Paulson Notes [Member] \| Subsequent Event [Member]
Subsequent Events (Textual)
Number of shares issued upon conversion	2,054,245
2020 Paulson Private Placement [Member] \| Subsequent Event [Member]
Subsequent Events (Textual)
Maximum principal amount issuable under paulson private placement			$ 3,000,000
Convertible promissory notes, percentage			13.00%
Principal amount			$ 1,854,800
Convertible note, description			The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $3,000,000 or a higher amount determined by the Board.
2020 Paulson Warrant [Member]
Subsequent Events (Textual)
Exercise price, per share					$ 1.87
Warrant expired date					Apr. 30, 2023
Purchase of common stock, desciption					Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction.
2020 Paulson Private Placement [Member]
Subsequent Events (Textual)
Cash commission, percentage					12.00%
Common stock, percentage					15.00%
2020 Paulson Private Placement [Member] \| Common Stock [Member]
Subsequent Events (Textual)
Exercise price, per share					$ 1.87
Broker Warrants [Member]
Subsequent Events (Textual)
Exercise price, per share					$ 1.87
Payroll Protection Program [Member]
Subsequent Events (Textual)
Loan maturity					2 years
Interest rate					1.00%
Funding loan received					$ 83,333

XML 27 R38.htm IDEA: XBRL DOCUMENT

Intangibles and Property and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Beginning Balance			$ 178,838
Less: amortization	$ (5,579)	$ (5,311)	(11,158)	$ (10,622)
Ending Balance	$ 167,680		$ 167,680
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life			12 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life			13 years

XML 28 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	6 Months Ended
Commitments and Contingencies (Details)	Mar. 31, 2020 USD ($)
Cash paid for amounts included in the measurement of lease liability:
Operating cash flows from operating leases
Right-of -use assets obtained in exchange for lease obligations:
Operating leases	$ 335,119

XML 29 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reclassification to equity upon conversion of convertible promissory notes	$ 239,522	$ 1,921,720
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period – September 30, 2018			$ 817,155
Change in fair value of warrant liability			18,568
Reclassification to equity upon conversion of convertible promissory notes			(835,723)
Balance as of end of period – March 31, 2019

XML 30 R13.htm IDEA: XBRL DOCUMENT

Convertible Promissory Notes and Warrant Agreements

6 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Convertible Promissory Notes and Warrant Agreements

NOTE 7 – Convertible Promissory Notes and Warrant Agreements

	As of March 31, 2020		As of September 30, 2019
Paulson convertible notes, principal	$	3,085,200	$	—
Accrued interest		152,036		—
Fair value adjustments		1,683,840		—
	$	4,921,076	$	—

Paulson Convertible Note Offering

During the six months ended March 31, 2020, 2019 Paulson Notes with a fair value of $239,522 were converted into 60,847 shares of common stock.

2017 Convertible Notes

As noted above, the 2017 Convertible Notes were converted into shares of common stock and not outstanding during the three and six month periods ended March 31, 2020.

XML 31 R17.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

6 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Stockholders' Deficit

NOTE 11 – Stockholders’ Deficit

Common Stock Offering

2019 Private Placement

2018 Private Placement

Warrant Activity and Summary

The following table summarizes warrant activity during the six month period ended March 31, 2020:

			Exercise Price		Weighted Average		Weighted Average
	Warrants		Per Warrant		Exercise Price		Term (years)
Outstanding and exercisable at September 30, 2019		7,265,598	$	1.80 - 3.00	$	2.55		3.60
Issued		1,124,389	$	1.87	$	1.87		4.26
Exercised		—	$	—	$	—		—
Forfeited		—	$	—	$	—		—
Outstanding and exercisable at March 31, 2020		8,389,987	$	1.80 - 3.00	$	2.45		3.26

XML 32 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Summary of supplemental cash flow information related to the operating lease

	Six months ended
	March 31, 2020

Cash paid for amounts included in the measurement of lease liability:
Operating cash flows from operating leases	$	—

Right-of -use assets obtained in exchange for lease obligations:
Operating leases	$	335,119

Summary of Supplemental balance sheet information related to the operating lease

	As of
	March 31, 2020
Right-of-use assets	$	308,055

Lease liability	$	339,157

Weighted average remaining lease term (years)		5.0
Weighted average discount rate		7.0	%

Summary of Maturity of the lease liability

	As of
	March 31, 2020
2020 (period from April 1, 2020 to September 30, 2020)	$	38,462
2021		77,884
2022		79,832
2023		81,827
2024		83,873
2025		42,454
Total lease payments		404,332
Less imputed interest		(65,175	)
Total		339,157
Short-term portion		(54,922	)
Long-term portion	$	284,235

XML 33 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of share-based compensation expense

	Three Months Ended				Six Months Ended
	March 31,				March 31,
	2020		2019		2020		2019
General and administrative	$	495,690	$	26,105	$	1,059,458	$	141,105
Research and development		36,091		44,112		60,000		48,092
Total share-based compensation	$	531,781	$	70,217	$	1,119,458	$	189,197

Schedule of weighted-average assumptions used black-scholes option-pricing model

	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2020			2019			2020			2019

Expected stock price volatility		54.3	%		50.7	%		52.8	%		50.2	%
Expected life of options (years)		5.4			6.0			5.7			5.9
Expected dividend yield		0	%		0	%		0	%		0	%
Risk free interest rate		1.4	%		2.6	%		1.7	%		2.7	%

XML 34 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - Convertible Notes [Member]	6 Months Ended
	Mar. 31, 2020 USD ($)
Convertible notes
Balance as of beginning of period – September 30, 2019
Fair value attributed to convertible promissory notes upon issuance	5,066,740
Conversion of convertible promissory notes to common stock	(239,522)
Change in fair value including accrued interest	93,858
Balance as of end of period – March 31, 2020	$ 4,921,076

XML 35 R8.htm IDEA: XBRL DOCUMENT

Going Concern

6 Months Ended

Mar. 31, 2020

Going Concern [Abstract]

Going Concern

NOTE 2 – Going Concern

The Company does not have adequate liquidity to fund its operations without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, these actions are not solely within the control of the Company. If the Company is unable to raise additional funds, or the Company's anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company's operations. If management is unable to obtain the necessary capital, it may have to cease operations.

XML 36 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
General and administrative	$ 1,035,256	$ 1,084,789	$ 2,347,422	$ 1,951,468
Research and development	342,102	436,311	843,921	645,479
Total operating expenses	1,377,358	1,521,100	3,191,343	2,596,947
Loss from operations	(1,377,358)	(1,521,100)	(3,191,343)	(2,596,947)
Interest expense		(20,534)	(2,697,507)	(284,557)
Net valuation change of instruments measured at fair value	31,716	(116,809)	(93,858)	(129,763)
Loss on notes extinguishment		(553,447)		(553,447)
Loss before income taxes	(1,345,642)	(2,211,890)	(5,982,708)	(3,564,714)
Provision for income taxes
Net loss	$ (1,345,642)	$ (2,211,890)	$ (5,982,708)	$ (3,564,714)
Net loss per share:
Basic and diluted	$ (0.10)	$ (0.20)	$ (0.43)	$ (0.34)
Number of shares used in per share calculations:
Basic and diluted	13,904,429	10,971,425	13,780,509	10,360,696

XML 37 R48.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	3 Months Ended		6 Months Ended
Income Taxes (Details)	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Income Taxes (Textual)
Effective tax rate	0.00%	0.00%	0.00%	0.00%
Income tax benefit

XML 38 R44.htm IDEA: XBRL DOCUMENT

Defined Contribution Plan (Details) - USD ($)	6 Months Ended
Defined Contribution Plan (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Defined Contribution Plan (Textual)
Employees defer compensation, percentage	100.00%
Employee deferrals contributions, description	The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through March 31, 2020.
Employee contributions, vesting percentage	100.00%
Employee deferrals, vesting term	6 years
Discretionary profit sharing contributions, vesting term	5 years
Contributions cost		$ (4,359)

XML 39 R40.htm IDEA: XBRL DOCUMENT

Intangibles and Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
Intangibles and Property and Equipment (Textual)
Amortization expense	$ 5,579	$ 5,311	$ 11,158	$ 10,622
Depreciation expense	$ 5,488	$ 0	$ 9,807	$ 0

ZIP 40 0001213900-20-012278-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-012278-xbrl.zip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end XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Management's Use of Estimates
Management's Use of Estimates

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk
Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company's cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of March 31, 2020, the Company did have deposits in excess of federally insured amounts by $497,244.

Common Stock Valuation
Common Stock Valuation

The Company has been utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company's common stock since September 30, 2019. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants' Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the "AICPA Valuation Framework"). The valuation methodology included estimates and assumptions that required the Company's judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates.

The fair value the Company's common stock is used as an input into the fair value determination of instruments recorded at fair value and stock option or other equity awards that the Company has issued.

Fair Value of Financial Instruments
Fair Value of Financial Instruments

The Company’s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

As of March 31, 2020 and September 30, 2019, the fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the convertible notes outstanding during the three and six month period ended March 31, 2020 were based on both the fair value of our common stock and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.

The estimated fair value of the convertible promissory notes of the Company that were outstanding during the three and six month period ended March 31, 2019 were based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes outstanding during fiscal 2019 were based on both the estimated fair value of our common stock and cash flow models discounted at the then current implied market rates evidenced in arms-length transactions representing expected returns by market participants for similar instruments during that period and were based on Level 3 inputs.

There were no transfers between fair value hierarchy levels during the three and six months ended March 31, 2020 and 2019.

The fair value of financial instruments measured on a recurring basis is as follows:

As of March 31, 2020

Description Total Level 1 Level 2 Level 3

Liabilities:

Convertible Notes $ 4,921,076 — — $ 4,921,076

Total liabilities at fair value $ 4,921,076 — — $ 4,921,076

The following table provides a roll-forward of the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the six month periods ended March 31 as follows:

2020

Convertible notes

Balance as of beginning of period – September 30, 2019 $ —

Fair value attributed to convertible promissory notes upon issuance 5,066,740

Conversion of convertible promissory notes to common stock (239,522 )

Change in fair value including accrued interest 93,858

Balance as of end of period – March 31, 2020 $ 4,921,076

2019

Warrant liability

Balance as of beginning of period – September 30, 2018 $ 817,155

Change in fair value of warrant liability 18,568

Reclassification to equity upon conversion of convertible promissory notes (835,723 )

Balance as of end of period – March 31, 2019 $ —

2019

Premium debt conversion derivatives

Balance as of beginning of period – September 30, 2018 $ 308,395

Change in fair value of premium debt conversion derivatives 111,195

Reclassification to equity upon conversion of convertible promissory notes (419,590 )

Balance as of end of period – March 31, 2019 $ —

Intellectual Property
Intellectual Property

The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.

Property and Equipment
Property and Equipment

Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to seven years and three years for software. Tangible assets acquired for research and development activities and that have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.

Impairment of Long-Lived Assets
Impairment of Long-Lived Assets

The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.

Debt Issuance Costs
Debt Issuance Costs

Debt issuance costs are recorded as a reduction of the convertible promissory notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed statements of operations.

Research and Development Costs
Research and Development Costs

Research and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (ASC) 730, Research and Development. Lastly, de minimis income from the sale of prototype products and related materials is offset against research and development expenses.

Warrant Liability
Warrant Liability

The Company issued warrants to purchase equity securities in connection with the issuance or amendment of the convertible promissory notes. The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying condensed statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders' (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the condensed statements of operations.

Premium Debt Conversion Derivatives
Premium Debt Conversion Derivatives

The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative at each reporting period in the condensed statements of operations.

Income Taxes
Income Taxes

For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

Net Loss Per Share
Net Loss Per Share

For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.

Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's convertible promissory notes, warrants, stock options and restricted stock units while outstanding are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and six month periods ended March 31, 2020 and 2019.

The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and six month periods ended March 31, 2020 and 2019:

2020 2019

Warrants 8,389,987 6,448,613

Stock options 1,355,512 600,209

Restricted stock units 59,090 —

Convertible notes 1,648,287 —

Recent Accounting Pronouncements
Recent Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company adopted the new standard on October 1, 2019 and did not have a material impact on the Company’s statements of comprehensive loss or statements of cash flows for agreements in place as of the adoption date. As such, the Company did not restate comparative periods and did not recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company elected the short-term lease expedient upon adoption of the standard. See NOTE 4 – Commitments and Contingencies with regard to a new operating lease that commenced after the adoption date on November 1, 2019.

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December 15, 2018 for public business entities, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new guidance on October 1, 2019, and the new guidance did not have an impact on the Company’s financial statements as of the adoption date.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13). The new guidance modifies the disclosure requirements in Topic 820 as follows:

● Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements.

● Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date.

● Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.

This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance and does not expect that it will have a material impact on its financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial statements.

X

- Definition
Disclosure of accounting policy for common stock valuation.
+ References
No definition available.
+ Details

Name: nmtc_CommonStockValuationPolicyTextBlock

Namespace Prefix: nmtc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy fori ntellectual property.
+ References
No definition available.
+ Details

Name: nmtc_IntellectualPropertyPolicyTextBlock

Namespace Prefix: nmtc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for premium debt conversion derivative.
+ References
No definition available.
+ Details

Name: nmtc_PremiumDebtConversionDerivativePolicyTextBlock

Namespace Prefix: nmtc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for warrant liability.
+ References
No definition available.
+ Details

Name: nmtc_WarrantLiabilityPolicyTextBlock

Namespace Prefix: nmtc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601
+ Details

Name: us-gaap_DebtPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Intangibles and Property and Equipment
6 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles and Property and Equipment
NOTE 5 – Intangibles and Property and Equipment

Intangibles

Intangible assets rollforward is as follows:

Useful Life

Net Intangibles, September 30, 2019 12-13 years $ 178,838

Less: amortization (11,158 )

Net Intangibles, March 31, 2020 $ 167,680

Amortization expense was $5,579 and $5,311 for the three months ended March 31, 2020 and 2019, respectively, and 11,158 and $10,622 for the six months ended March 31, 2020 and 2019, respectively.



Property and Equipment

Property and equipment held for use by category are presented in the following table:

As of

March 31,
2020 September 30,
2019

Equipment and furniture $ 99,181 $ 56,457

Software 1,895 1,895

Total property and equipment 101,076 58,352

Less accumulated depreciation (16,133 ) (6,326 )

Property and equipment, net $ 84,943 $ 52,026

Depreciation expense was $5,488 and zero for the three months ended March 31, 2020 and 2019, respectively, and $9,807 and zero for the six months ended March 31, 2020 and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation
6 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation
NOTE 9 – Stock-Based Compensation

Stock-based compensation expense was included in general and administrative and research and development expenses as follows in the accompanying condensed statements of operations:

Three Months Ended Six Months Ended

March 31, March 31,

2020 2019 2020 2019

General and administrative $ 495,690 $ 26,105 $ 1,059,458 $ 141,105

Research and development 36,091 44,112 60,000 48,092

Total share-based compensation $ 531,781 $ 70,217 $ 1,119,458 $ 189,197

Stock Options

During the three month period ended March 31, 2020 and 2019, under the 2017 Equity Incentive Plan (the “2017 Plan”), the Company granted 20,000 and 150,548 stock options, respectively, to its employees, consultants and scientific advisory board members. During the six month periods ended March 31, 2020 and 2019, under the 2017 Plan, the Company granted 820,000 and 325,548 stock options, respectively, to its employees, consultants and scientific advisory board members. Vesting generally occurs over an immediate to 48 month period based on a time of service condition although vesting acceleration is provided under one grant in the event that certain milestones are met. The grant date fair value of the grants issued during the three month periods ended March 31, 2020 and 2019 was $1.15 and $1.11 per share, respectively. The grant date fair value of the grants issued during the six month periods ended March 31, 2020 and 2019 was $1.06 and $1.12 per share, respectively. The total expense for the three months ended March 31, 2020 and 2019 related to stock options was $88,806 and $46,654, respectively. The total expense for the six month periods ended March 31, 2020 and 2019 related to stock options was $526,888 and $46,654, respectively. The total number of stock options outstanding as of March 31, 2020 and September 30, 2019 was 1,355,512 and 845,840, respectively.



The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and six month periods ended March 31, 2020 and 2019:

Three Months Ended Six Months Ended

March 31, March 31,

2020 2019 2020 2019

Expected stock price volatility 54.3 % 50.7 % 52.8 % 50.2 %

Expected life of options (years) 5.4 6.0 5.7 5.9

Expected dividend yield 0 % 0 % 0 % 0 %

Risk free interest rate 1.4 % 2.6 % 1.7 % 2.7 %

During the three and six month periods ended March 31, 2020, 46,865 and 422,694 stock options vested, respectively, and 39,675 stock options vested during the three and six months ended March 31, 2019. During the three and six month periods ended March 31, 2020, 260,306 and 267,803 stock options were forfeited, respectively, and no options were forfeited during the three and six month periods ended March 31, 2019.

Restricted Stock Units

During the three and six month periods ended March 31, 2020, 167,851 restricted stock units (“RSUs”) were granted. During the three and six month periods ended March 31, 2019, no RSUs were granted. During the three and six month periods ended March 31, 2020, 122,767 and 133,272 RSUs vested, respectively. No RSUs vested during the three and six month periods ended March 31, 2019. The total expense for the three and six month period ended March 31, 2020 related to the RSU’s was $289,394 and $314,395, respectively. No expense was recognized related to the RSUs during the three and six month periods ended March 31, 2019. The number of RSUs forfeited during the three and six month periods ended March 31, 2020 was zero and 7,003, respectively. No RSUs were forfeited during the three and six month periods ended March 31, 2019.

Other Stock-Based Awards

In October 2019, two consulting agreements were executed whereby up to 115,000 shares of common stock were issuable of which 90,000 shares of common stock were issued and vested as of March 31, 2020 under these agreements. Vesting is based on a time-based vesting condition ranging over a three to nine month period commencing upon the execution of the consulting agreements. In February 2020, an additional consulting agreement was executed whereby up to 90,000 shares of common stock were issuable of which 36,000 shares of common stock were issued and vested as of March 31, 2020 under this agreement. Compensation expense related to the stock awards granted under these consulting agreements amounted to $153,581 and $278,175 and was included in the total stock-based expense referenced above for the three and six month periods ended March 31, 2020, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which ranged from $2.00 to $2.65 per share.

In February 2018, 250,000 shares of common stock were reserved as a result of a consulting agreement for investor relations services executed in February 2018. Under the agreement, zero and 50,000 shares of common stock were awarded during the three and six month period ended March 31, 2019, respectively, on a time-based vesting condition that was met in November 2018. The compensation expense related to the vested common shares was included in the total stock-based expense referenced above which totaled zero and $115,000 for the three and six month periods ended March 31, 2019, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which was $2.30 per share. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies.

As of March 31, 2019, the Company had formal obligation to issue future common stock options relating to several consulting agreements. The corresponding stock-based compensation expense related to the stock-based award liabilities amounted to $23,563 and $27,543 during the three and six month periods ended March 31, 2019, respectively, and was included in general and administrative expense in the accompanying condensed statements of operations.

General

As of March 31, 2020, 2,063,506 shares were available for future issuance on a combined basis under the 2016 Equity Incentive Plan and 2017 Plan. Unrecognized stock-based compensation was $0.8 million as of March 31, 2020. The unrecognized share-based expense is expected to be recognized over a weighted average period of 2.9 years.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R36.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies (Details 2)

Mar. 31, 2020

USD ($)

Commitments and Contingencies Disclosure [Abstract]

2020 (period from April 1, 2020 to September 30, 2020) $ 38,462

2021 77,884

2022 79,832

2023 81,827

2024 83,873

2025 42,454

Total lease payments 404,332

Less imputed interest (65,175)

Total 339,157

Short-term portion (54,922)

Long-term portion $ 284,235

X

- Definition
Imputed interest.
+ References
No definition available.
+ Details

Name: nmtc_ImputedInterest

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt and lease obligation, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of short-term lease commitment.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918705-209980
+ Details

Name: us-gaap_ShortTermLeaseCommitmentAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Details 4) - shares
6 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive computation of diluted net loss per share 8,389,987 6,448,613

Stock options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive computation of diluted net loss per share 1,355,512 600,209

Restricted stock units [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive computation of diluted net loss per share 59,090

Convertible Notes [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Anti-dilutive computation of diluted net loss per share 1,648,287

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nmtc_ConvertibleNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R23.htm IDEA: XBRL DOCUMENT v3.20.1

Accrued Expenses (Tables)
6 Months Ended

Mar. 31, 2020

Payables and Accruals [Abstract]

Schedule of accrued expenses
As of

March 31,
2020 September 30,
2019

Legal services $ — $ 228,709

Accrued issuance costs 50,400 50,400

Accrued payroll 126,001 171,087

Lease liability, short-term 54,922 —

Other 60,551 167,525

$ 291,874 $ 617,721

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R27.htm IDEA: XBRL DOCUMENT v3.20.1

Going Concern (Details) - USD ($)

Mar. 31, 2020

Sep. 30, 2019

Going Concern (Textual)

Accumulated deficit $ 23,221,579 $ 17,238,871

X

- References
No definition available.
+ Details

Name: nmtc_GoingConcernTextualAbstract

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 49 R46.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation (Details 1) - Stock Options [Member]
3 Months Ended 6 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Mar. 31, 2020

Mar. 31, 2019

Offsetting Assets [Line Items]

Expected stock price volatility 54.30% 50.70% 52.80% 50.20%

Expected life of options (years) 5 years 4 months 24 days 6 years 5 years 8 months 12 days 5 years 10 months 25 days

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Risk free interest rate 1.40% 2.60% 1.70% 2.70%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OffsettingAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R42.htm IDEA: XBRL DOCUMENT v3.20.1

Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)

Mar. 31, 2020

Sep. 30, 2019

Short-term Debt [Line Items]

Accrued interest $ 152,036

Fair value adjustments 1,683,840

Total 4,921,076

Paulson convertible notes, principal [Member]

Short-term Debt [Line Items]

Total $ 3,085,200

X

- Definition
Including the current and noncurrent portions, at fair value value as of the balance sheet date of a written promise to pay a note, initially due within one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ References
No definition available.
+ Details

Name: nmtc_ConvertiblePromissoryNotesPayable

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of principal balance component of the Paulson Notes.
+ References
No definition available.
+ Details

Name: nmtc_ConvertiblePromissoryNotesPayablePrincipalBalance

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value in excess of principal and accrued interest related to debt instrument payable.
+ References
No definition available.
+ Details

Name: nmtc_FairValueAdjustmentOfConvertibleNotes

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of interest payable on debt, including, but not limited to, trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_InterestPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertiblePromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Operating activities

Net loss $ (5,982,708) $ (3,564,714)

Adjustments to reconcile net loss to net cash used in operating activities:

Amortization and depreciation 20,965 10,622

Stock-based compensation 1,119,458 189,197

Non-cash interest on convertible notes 1,831,940 51,333

Non-cash discount amortization on convertible notes 233,224

Revaluation of convertible notes 93,858

Revaluation of premium conversion derivatives and warrant liability 129,763

Issuance costs attributed to financing activities 865,567

Loss on notes extinguishment 553,447

Lease liability principal payment deferral 4,038

Right-of-use asset depreciation adjustment (4,038)

Change in assets and liabilities:

Prepaid and other assets (40,303) (74,574)

Accounts payable and other accrued liabilities (383,855) (104,578)

Net cash used in operating activities (2,475,078) (2,576,280)

Investing activities

Purchase of fixed assets and intangible assets (40,224) (65,000)

Net cash used in investing activities (40,224) (65,000)

Financing activities

Proceeds from issuance of convertible promissory notes 3,234,800

Issuance costs related to convertible notes (417,176)

Proceeds from unsecured loans 245,000

Proceeds from issuance of common stock in connection with private placements 255,000 3,768,032

Proceeds from issuance of warrants in connection with private placements 1,416,915

Exercise of warrants 416,333

Exercise of stock options 1,488 3,273

Repayment of unsecured loans (299,000)

Issuance costs related to private placements (72,315) (617,134)

Net cash provided by financing activities 3,001,797 4,933,419

Net increase in cash 486,495 2,292,139

Cash at beginning of period 260,749 13,260

Cash at end of period 747,244 2,305,399

Supplemental non-cash financing and investing transactions:

Conversion of convertible promissory notes to equity 1,678,361

Exercise of premium conversion derivative liability 419,590

Reclassification of warrant liability to equity 835,723

Unpaid issuance costs attributed to convertible notes and private placement 28,756 230,959

Broker warrants issued in connection with convertible notes 419,635

Purchased fixed assets in accounts payable and accrued expenses 2,500

Operating lease right of use asset obtained in exchange for operating lease $ 335,119

X

- Definition
Amount of expense for share based compensation.
+ References
No definition available.
+ Details

Name: nmtc_AllocatedShareBasedCompensation

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_ConversionOfConvertiblePromissoryNotesToEquity

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_DebtConversionConvertedInstrumentWarrantsIssued

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_ExerciseOfPremiumConversionDerivativeLiability

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_ExerciseOfWarrants

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Issuance costs related to private placements.
+ References
No definition available.
+ Details

Name: nmtc_IssuanceCostsRelatedToPrivatePlacements

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_LeaseLiabilityPrincipalPaymentDeferralAmount

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of non-cash interest on short-term and convertible promissory notes.
+ References
No definition available.
+ Details

Name: nmtc_NonCashInterestOnShortTermAndConvertiblePromissoryNotes

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_ProceedsFromExerciseOfStockOption

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of common stock in connection with private placements.
+ References
No definition available.
+ Details

Name: nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of warrants with private placement.
+ References
No definition available.
+ Details

Name: nmtc_ProceedsFromIssuanceOfWarrantsWithPrivatePlacement

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Purchased fixed assets in accounts payable and accrued expenses.
+ References
No definition available.
+ Details

Name: nmtc_PurchasedFixedAssetsInAccountsPayableAndAccruedExpenses

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_ReclassificationOfWarrantLiabilityToEquity

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revaluation of convertible notes.
+ References
No definition available.
+ Details

Name: nmtc_RevaluationOfConvertibleNotes

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revaluation of premium conversion derivatives and warrant liability.
+ References
No definition available.
+ Details

Name: nmtc_RevaluationOfPremiumConversionDerivativesAndWarrantLiability

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_RightOfUseAssetDepreciationAdjustment

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfUnsecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfUnsecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 53 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Balance Sheets - USD ($)

Mar. 31, 2020

Sep. 30, 2019

Current assets:

Cash $ 747,244 $ 260,749

Prepaid and other assets 81,305 41,002

Total current assets 828,549 301,751

Right-of-use asset 308,055

Intangible assets, net 167,680 178,838

Property and equipment, net 84,943 52,026

Total assets 1,389,227 532,615

Current liabilities:

Accounts payable 1,077,225 1,152,472

Accrued expenses 291,874 617,721

Convertible promissory notes (Note 7) 4,921,076

Total current liabilities 6,290,175 1,770,193

Lease liability 284,235

Total liabilities 6,574,410 1,770,193

Commitments and contingencies (Note 4)

Stockholders' deficit:

Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2020 and September 30, 2019; no shares issued or outstanding as of March 31, 2020 and September 30, 2019.

Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and September 30, 2019; 14,022,423 and 13,493,705 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively. 14,023 13,494

Additional paid-in capital 18,022,373 15,987,799

Accumulated deficit (23,221,579) (17,238,871)

Total stockholders' deficit (5,185,183) (1,237,578)

Total liabilities and stockholders' deficit $ 1,389,227 $ 532,615

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Intangibles and Property and Equipment (Tables)
6 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets
Useful Life

Net Intangibles, September 30, 2019 12-13 years $ 178,838

Less: amortization (11,158 )

Net Intangibles, March 31, 2020 $ 167,680

Schedule of property and equipment

As of

March 31,
2020 September 30,
2019

Equipment and furniture $ 99,181 $ 56,457

Software 1,895 1,895

Total property and equipment 101,076 58,352

Less accumulated depreciation (16,133 ) (6,326 )

Property and equipment, net $ 84,943 $ 52,026

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Deficit (Tables)
6 Months Ended

Mar. 31, 2020

Stockholders' Equity Note [Abstract]

Schedule of warrant activity

Exercise
Price Weighted
Average Weighted
Average

Warrants Per Warrant Exercise Price Term (years)

Outstanding and exercisable at September 30, 2019 7,265,598 $ 1.80 - 3.00 $ 2.55 3.60

Issued 1,124,389 $ 1.87 $ 1.87 4.26

Exercised — $ — $ — —

Forfeited — $ — $ — —

Outstanding and exercisable at March 31, 2020 8,389,987 $ 1.80 - 3.00 $ 2.45 3.26

X

- Definition
The entire disclosure of warrant activity.
+ References
No definition available.
+ Details

Name: nmtc_SummaryOfWarrantActivityTableTextBlock

Namespace Prefix: nmtc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R47.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Feb. 29, 2020

Oct. 31, 2019

Mar. 31, 2020

Mar. 31, 2019

Mar. 31, 2020

Mar. 31, 2019

Sep. 30, 2019

Feb. 28, 2018

Restricted Stock [Member]

Stock-Based Compensation (Textual)

Stock options vested 122,767 0 133,272 0

Compensation expense associated with restricted common stock $ 289,394 $ 0 $ 314,395 $ 0

Number of options, granted 167,851 0 167,851 0

RSUs forfeited shares 0 0 7,003 0

General and Administrative Expense [Member]

Stock-Based Compensation (Textual)

Compensation expense related to the stock awards $ 23,563 $ 27,543

2017 Equity Incentive Plan [Member]

Stock-Based Compensation (Textual)

Fair value of common stock price per share $ 1.15 $ 1.11 $ 1.06 $ 1.12

Compensation expense related to the stock awards $ 88,806 $ 46,654 $ 526,888 $ 46,654

Stock options vested 46,865 39,675 422,694 39,675

Number of options, granted 20,000 150,548 820,000 325,548

Unrecognized share-based expense is expected to be recognized over a weighted average period 2 years 10 months 25 days

Number of options, forfeited 260,306 0 267,803 0

Total number of stock options outstanding 1,355,512 1,355,512 845,840

Stock-Based Awards [Member]

Stock-Based Compensation (Textual)

Reserved shares of common stock for issuance 250,000

Compensation expense related to the stock awards $ 153,581 $ 278,175

Stock options vested 60,000 0 50,000

Stock-based services expense $ 0 $ 115,000

Common stock related to the award liability includes stock options $ 2.30

Stock-Based Awards [Member] | Minimum [Member]

Stock-Based Compensation (Textual)

Fair value of common stock price per share $ 2.00

Stock-Based Awards [Member] | Maximum [Member]

Stock-Based Compensation (Textual)

Fair value of common stock price per share $ 2.65

Stock-Based Awards [Member] | Consultant [Member]

Stock-Based Compensation (Textual)

Shares of common stock 90,000 115,000

Stock-Based Awards [Member] | Consultant One [Member]

Stock-Based Compensation (Textual)

Shares of common stock 36,000 90,000

Stock Option [Member] | 2016 and 2017 Equity Incentive Plans [Member]

Stock-Based Compensation (Textual)

Unrecognized stock-based compensation $ 800,000 $ 800,000

Shares available for future grant issuance 2,063,506 2,063,506

X

- Definition
Fair value of underlying common stock for the period.
+ References
No definition available.
+ Details

Name: nmtc_CommonStockRelatedToAwardLiabilityIncludesStockOptions

Namespace Prefix: nmtc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of common stock price per share.
+ References
No definition available.
+ Details

Name: nmtc_FairValueOfCommonStockPricePerShare

Namespace Prefix: nmtc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
It represents the actual shares available for future grant issuance.
+ References
No definition available.
+ Details

Name: nmtc_SharesAvailableForFutureGrantIssuance

Namespace Prefix: nmtc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: nmtc_StockBasedCompensationTextualAbstract

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stock-based services expense.
+ References
No definition available.
+ Details

Name: nmtc_StockbasedServicesExpense

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of cost expensed and capitalized for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares related to Restricted Stock Award forfeited during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=nmtc_TwoZeroOneSevenPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=nmtc_StockOptionLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=nmtc_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=nmtc_ConsultantOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.1

Convertible Promissory Notes and Warrant Agreements (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Dec. 03, 2019

Feb. 28, 2019

Mar. 31, 2020

Mar. 31, 2019

Mar. 31, 2020

Mar. 31, 2019

Nov. 01, 2019

Convertible Promissory Notes and Warrant Agreements (Textual)

Net valuation change of instruments measured at fair value $ 31,716 $ (116,809) $ (93,858) $ (129,763)

Paulson Private Placement [Member]

Convertible Promissory Notes and Warrant Agreements (Textual)

Issuance cost 419,635

Issuance cost include cash commission 388,176

Legal and third party fee $ 57,756

Paulson Private Placement [Member] | Common Stock [Member]

Convertible Promissory Notes and Warrant Agreements (Textual)

Warrants exercise price $ 1.87 $ 1.87

Warrants to purchase of common stock shares 259,476

Exercise price, per share $ 1.87 $ 1.87

Issuance cost $ 865,567

2017 Convertible Notes [Member]

Convertible Promissory Notes and Warrant Agreements (Textual)

Convertible notes bear interest at fixed rate 8.00% 8.00%

Principal amount $ 1,540,000 $ 1,540,000

Convertible notes conversion price per common share $ 3.00 $ 3.00

Convertible promissory notes converted into common stock 839,179

Shares of common stock issuable upon exercise of warrants 839,179

Issued new warrants exercisable common stock 839,179

Warrant exercise term 4 years 9 months 18 days

Interest on principal amount 30,800

Interest related to amortization of discounts related to bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amount 233,223

Fair value changes related to underlying premium conversion derivative and warrant liability amounted to benefit 6,265

Fair value changes related to underlying premium conversion derivative and warrant liability amounted to expense 6,689

Paulson Convertible Note Offering [Member]

Convertible Promissory Notes and Warrant Agreements (Textual)

Convertible notes bear interest at fixed rate 13.00%

Principal amount $ 3,234,800

Gross proceeds of equity qualified financing $ 3,000,000

Equity qualified financing, description (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the 2019 Qualified Financing or (B) the ten day VWAP of the common stock prior to the first closing of a 2019 Qualified Financing. If a change of control transaction occurs prior to a 2019 Qualified Financing or the maturity date, the 2019 Paulson Notes would become payable on demand as of the closing date of such transaction

Description of maximum voting power of surviving entity Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.

Warrants exercise price $ 1.87 $ 1.87

Warrants exercisable date of issuance and expire Nov. 01, 2022

Convertible notes to interest expense $ 1,831,940

Warrant issuance in connection with execution note agreement 864,913 60,847

Maturity date May 01, 2020

Interest on principal amount $ 100,269 100,269 $ 154,144 154,144

Net valuation change of instruments measured at fair value (31,716) (31,716) (31,716) (31,716)

Net valuation of instruments measured at fair value $ 93,858 $ 93,858 $ 93,858 $ 93,858

Warrants, description (i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87.

X

- Definition
Issued new warrants exercisable common stock.
+ References
No definition available.
+ Details

Name: nmtc_AdditionalDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: nmtc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant exercise term.
+ References
No definition available.
+ Details

Name: nmtc_ClassofWarrantExerciseTerm

Namespace Prefix: nmtc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of maximum voting power of surviving entity.
+ References
No definition available.
+ Details

Name: nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity qualified financing, description on Convertible Note Offering.
+ References
No definition available.
+ Details

Name: nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of warrants issued in connection with the execution of the note agreement.
+ References
No definition available.
+ Details

Name: nmtc_ExecutionOfNoteAgreementWarrantsIssued

Namespace Prefix: nmtc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value changes related to underlying premium conversion derivative and warrant liability amounted to benefit.
+ References
No definition available.
+ Details

Name: nmtc_FairValueChangesRelatedToUnderlyingPremiumConversionDerivativeAndWarrantLiabilityAmountedToBenefit

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value changes related to underlying premium conversion derivative and warrant liability amounted to expense.
+ References
No definition available.
+ Details

Name: nmtc_FairValueChangesRelatedToUnderlyingPremiumConversionDerivativeAndWarrantLiabilityAmountedToExpense

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of threshold equity round of qualified financing.
+ References
No definition available.
+ Details

Name: nmtc_GrossProceedsFromEquityQualifiedFinancing

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest on principal amount.
+ References
No definition available.
+ Details

Name: nmtc_InterestOnPrincipalAmount

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest related to amortization of discounts related to the bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amount.
+ References
No definition available.
+ Details

Name: nmtc_InterestRelatedToAmortizationOfDiscountsRelatedToBifurcationOfPremiumDerivativeLiabilitySeparationOfWarrantsRevaluationDiscountsAndIssuanceCostsAmount

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issuance cost include cash commission.
+ References
No definition available.
+ Details

Name: nmtc_IssuanceCostIncludeCashCommission

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to issuance of financial instruments.
+ References
No definition available.
+ Details

Name: nmtc_LegalAndThirdPartyFee

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Net valuation change of instruments measured at fair value.
+ References
No definition available.
+ Details

Name: nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net valuation change of instruments measured at fair value.
+ References
No definition available.
+ Details

Name: nmtc_NetValuationOfIncreaseOfInstrumentsMeasuredAtFairvalue

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total non-cash and cash outflow during the period which has been attributed to third parties in connection with debt issuance costs.
+ References
No definition available.
+ Details

Name: nmtc_PaymentsOfIssuanceCost

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Warrants, description.
+ References
No definition available.
+ Details

Name: nmtc_WarrantsDescription

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants to be issued for the right to purchase common shares at stated exercise price.
+ References
No definition available.
+ Details

Name: nmtc_WarrantsToPurchaseOfCommonStockShares

Namespace Prefix: nmtc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the warrants or rights are exercisable, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(3))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the debt instrument was offered for sale, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_DebtInstrumentOfferingDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmtc_PaulsonPrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=nmtc_ConvertibleDebtOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R7.htm IDEA: XBRL DOCUMENT v3.20.1

Description of Business and Basis of Presentation
6 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business and Basis of Presentation

NOTE 1 – Description of Business and Basis of Presentation

NeuroOne Medical Technologies Corporation (the "Company"), a Delaware Corporation, is an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson's disease, essential tremors, and other brain related disorders.

To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology. The Company received clearance to market the initial device and expect to submit for additional clearance for a second product by end of year. The Company is also evaluating different options for commercializing the current approved device.

The Company is based in Eden Prairie, Minnesota.

COVID-19

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus ("COVID-19") as a global pandemic, which continues to spread throughout the United States and around the world. As a result of the COVID-19 pandemic, the Company has experienced delays and disruptions in its pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, and research and development operations. The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic may impact our business and pre-clinical and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic may also impact the Company's ability to secure additional financing or its ability to up-list from its current OTC Market ("OTCQB"), and may result in further modifications to its debt agreements. See NOTE 12 – Subsequent Events. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company's results of future operations, financial position, and liquidity in fiscal year 2020.

Basis of presentation

The accompanying condensed financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosures required by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended September 30, 2019 included in the Annual Report on Form 10-K. The condensed balance sheet at September 30, 2019 was derived from the audited financial statements of the Company.

In December 2019, the Company merged its wholly owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the Company's wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company did not have any remaining entities that required consolidation for financial statement reporting purposes.

In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R3.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Balance Sheets (Parenthetical) - $ / shares

Mar. 31, 2020

Sep. 30, 2019

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 14,022,423 13,493,705

Common stock, shares outstanding 14,022,423 13,493,705

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies
6 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
NOTE 4 – Commitments and Contingencies

WARF License amendment

The Company entered into an Amended and Restated Exclusive Start-up Company License Agreement (the "WARF License") with Wisconsin Alumni Research Foundation ("WARF") on January 21, 2020, which amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1, 2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019.

The WARF License grants to the Company an exclusive license to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. The Company has agreed to pay WARF a royalty equal to a single-digit percentage of its product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. If the Company or any of its sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by the Company if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License.

WARF may terminate the WARF License if the Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, or breaches any other covenant in the WARF License and fails to remedy such default in ninety (90) days or in the event of certain bankruptcy events involving the Company. WARF may also terminate the WARF License on ninety (90) days' notice if the Company fails to have commercial sales of one or more FDA-approved products under the WARF License by June 30, 2020. The WARF License otherwise expires by its terms (i) on the date that no valid claims on the patents licensed thereunder remain or (ii) upon the cessation for more than four (4) calendar quarters of the payment, once begun, of earned royalties under certain sections of the WARF License. The Company expects the latest expiration of a licensed patent to occur in 2030.

In addition, WARF reserves the right to grant non-profit research institutions and government agencies non-exclusive licenses to practice and use the inventions of the licensed patents for non-commercial research purposes, and the Company grants WARF a non-exclusive, sub licensable, royalty-free right and license for non-commercial research purposes to use improvements to the licensed patents. In the event that the Company discontinues use or commercialization of the licensed patents or improvements thereon, the Company must grant WARF an option to obtain a non-exclusive, sub-licensable royalty-bearing license to use the improvements for commercial purposes.

Legal

From time to time, the Company is subject to litigation and claims arising in the ordinary course of business. In May 2017, NeuroOne received a letter from PMT Corporation ("PMT"), the former employer of Mark Christianson and Wade Fredrickson. PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer's prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with contracts. The letter, which purported to attach a noncompete agreement signed by Mr. Fredrickson, demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne's systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer.

On March 29, 2018, the Company was served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. The complaint purported to attach Mr. Fredrickson's noncompete agreement as Exhibit A. In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT's contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition. PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys' fees, costs and interest.

On April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal states that: the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff's claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition. On January 7, 2019, the judge granted the motion for dismissal with respect to PMT's claim for breach of the duty of good faith and fair dealing, and denied the motion for dismissal with respect to the other claims presented.



In April 2019, PMT served the Company, NeuroOne, Inc and Christianson with a proposed Second Amended Complaint, which included new claims against the Company and NeuroOne, Inc for tortious interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne Inc. and Christianson. On June 28, 2019 the Company presented evidence indicating that PMT had participated in a fraud on the Court and sought an Order that PMT had waived the attorney client privilege.

On July 16, 2019, the defendants served PMT with a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal of the case and an award of attorneys' fees. The Company, NeuroOne Inc and Mr. Christianson further intend to move for summary judgment on all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process.

On August 30, 2019, the Hennepin County District Court heard dispositive motions in this case. The district court judge indicated some claims would likely be tried to a jury and encouraged the parties to settle.

On September 12, 2019 the district court heard NeuroOne's motion for sanctions. The district court held the sanctions hearing on December 17, 2019 and December 18, 2019 and indicated that a ruling would be made in approximately 90 days. NeuroOne and Mark Christianson (who has not worked for PMT since February 2012) intend to continue to defend themselves vigorously. The Court issued multiple rulings on the Company's request for summary judgment and sanctions against PMT in April 2020. See NOTE 12 – Subsequent Events.

Facility Lease

On October 7, 2019, the Company entered into a non-cancellable lease agreement (the "Lease") with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the "Landlord") pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the "Premises"). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the "Term"). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord's annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.

Prior to the October 2019 Lease, the Company entered into a non-cancellable facility lease for its operations and headquarters for an eleven month term beginning on December 1, 2018. The monthly rent under that lease was $4,763.

During the three month periods ended March 31, 2020 and 2019, rent expense associated with the facility leases amounted to $25,862 and $14,289, respectively, and $47,866 and $19,052 during the six month periods ended March 31, 2020 and 2019, respectively.



Supplemental cash flow information related to the operating lease was as follows:

Six months
ended

March 31,
2020

Cash paid for amounts included in the measurement of lease liability:

Operating cash flows from operating leases $ —

Right-of -use assets obtained in exchange for lease obligations:

Operating leases $ 335,119

Supplemental balance sheet information related to the operating lease was as follows:

As of

March 31,
2020

Right-of-use assets $ 308,055

Lease liability $ 339,157

Weighted average remaining lease term (years) 5.0

Weighted average discount rate 7.0 %

Maturity of the lease liability was as follows:

As of

March 31, 2020

2020 (period from April 1, 2020 to September 30, 2020) $ 38,462

2021 77,884

2022 79,832

2023 81,827

2024 83,873

2025 42,454

Total lease payments 404,332

Less imputed interest (65,175 )

Total 339,157

Short-term portion (54,922 )

Long-term portion $ 284,235

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1

Defined Contribution Plan
6 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

Defined Contribution Plan
NOTE 8 – Defined Contribution Plan

The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through March 31, 2020.

Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee’s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee’s date of hire. No matching contributions were made during the three and six month periods ended March 31, 2020. During the six month period ended March 31, 2019, there was a benefit reduction adjustment of $(4,359) given an overpayment. There were no matching contributions during the three month period ended March 31, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events
6 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

NOTE 12 – Subsequent Events

Amendment of 2019 Paulson Notes

On April 24, 2020, the Company and holders of a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the "Second Paulson Amendment") to, among other things:

i. Extend the Maturity Date – The Second Paulson Amendment extends the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either case, unless a change of control transaction happens prior to such date);

ii. Revise Optional Conversion Terms – The Second Paulson Amendment provides that the amount of shares to be received upon the a subscriber's optional conversion of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) will be equal to: (1) the Outstanding Balance of such subscriber's 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion; and

iii. Revise the Registration Date – The Second Paulson Amendment provides that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber has converted all or a majority of the Outstanding Balance of such subscriber's 2019 Paulson Note prior to such date; (2) the final closing a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.

There were no other significant changes to terms under the Second Paulson Amendment.

2019 Paulson Note Conversion

Between April 24, 2020 and May 1, 2020, certain holders elected to convert outstanding principal and accrued and unpaid interest of 2019 Paulson Notes in the amount of $2,633,280 into 2,054,245 shares of common stock.

Paulson 2020 Convertible Note Financing

On April 30, 2020, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the "2020 Paulson Private Placement"), agreed to issue and sell to the investors up to $3 million of 13% convertible promissory notes (each, a "2020 Paulson Note" and collectively, the "2020 Paulson Notes") and warrants (each, a "2020 Paulson Warrant" and collectively, the "2020 Paulson Warrants") to purchase shares of the Company's common stock.

Between April 30, 2020 and May 8, 2020, the Company issued 2020 Paulson Notes in an aggregate principal amount of $2,469,800 to the Subscribers. The Company may conduct any number of additional closings so long as the aggregate amount of gross proceeds does not exceed $6,000,000 or a higher amount determined by the Board.

The 2020 Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of (i) six months following the final closing of the 2020 Paulson Private Placement, (ii) six months following July 31, 2020, and (iii) a change of control transaction. If the Company raises more than $5,000,000 in an equity financing before the maturity date (the "2020 Qualified Financing"), without any action on the part of the Subscribers, all of the outstanding principal and accrued and unpaid interest of the Notes (the "Outstanding Balance") shall convert into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurs and (B) the volume weighted average price of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.

If the Company announces a transaction between the Company and any other company (or an affiliate of any such company) that is included in the S&P 500 Health Care Index as published from time to time by S&P Dow Jones Indices LLC that includes an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration, manufacturing, distribution, licensing or supply of the Company's products (a "Strategic Transaction") before the maturity date, without any action on the part of the subscribers, the Outstanding Balance shall be converted into that number of shares of common stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the Company of a Strategic Transaction.

At any time, at the sole election of the holder of such 2020 Paulson Note, all or a portion of the Outstanding Balance may be converted into that number of shares of common stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.

If a change of control transaction occurs prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.

Each 2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. The 2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction.

In connection with the 2020 Paulson Private Placement, Paulson will receive a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes, and at the final closing of the 2020 Paulson Private Placement, Paulson will receive 7-year warrants to purchase an amount of common stock equal to 15% of the total gross proceeds received by the Company in the 2020 Paulson Private Placement, divided by 1.87 (the "Broker Warrants"). The Broker Warrants will have an exercise price equal to $1.87.

2020 Paulson Note Conversions

Between May 4, 2020 and May 12, 2020, certain Subscribers elected to convert $50,153 of the outstanding principal and interest of such Subscribers' 2020 Paulson Notes into 38,335 shares of common stock.

Payroll Protection Program

The CARES Act, signed into law in March 2020, established the Paycheck Protection Program ("PPP"). The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over an 8 week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments may be made without penalty. In April 2020, the Company received loan funding of approximately $83,333 under the PPP.

Amendment to Veritas Consulting Agreement

On April 22, 2020, the Company entered into an amendment (the "Amendment") to the Consulting Agreement, by and between the Company and Veritas Consulting Group Inc. ("Veritas"). Pursuant to the Amendment, the Company issued Veritas an additional 35,000 shares in exchange for consulting services.

PMT Litigation

On April 29, 2020, the district court granted the Company's motion for sanctions. Additionally, the district court granted the Company's motion for summary judgment in part with respect to the counts for Christianson's breach of non-confidentiality agreement, Fredrickson's breach of confidentiality covenants, and the creation of a constructive trust and denied the Company's motion for summary judgment on all other counts.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Mar. 31, 2020

Mar. 31, 2019

Nov. 01, 2019

Commitments and Contingencies (Textual)

Royalty payments - 2020 $ 50,000 $ 50,000

Royalty payments - 2021 100,000 100,000

Royalty payments - 2022 150,000 150,000

Facility lease term 65 months

Monthly lease rent $ 4,763

Lease rent expense,description Prior to the October 2019 Lease, the Company entered into a non-cancellable facility lease for its operations and headquarters for an eleven month term beginning on December 1, 2018. The monthly rent under that lease was $4,763.

Facility lease agreement, description On October 7, 2019, the Company entered into a non-cancellable lease agreement (the “Lease”) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the “Landlord”) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the “Term”). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.

Rent expense $ 25,862 $ 14,289 $ 47,866 $ 19,052

X

- References
No definition available.
+ Details

Name: nmtc_CommitmentsAndContingenciesTextualAbstract

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Monthly lease rent.
+ References
No definition available.
+ Details

Name: nmtc_MonthlyLeaseRent

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of royalty minimum payments year one.
+ References
No definition available.
+ Details

Name: nmtc_RoyaltyMinimumPaymentsYearOne

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of royalty minimum payments year third year.
+ References
No definition available.
+ Details

Name: nmtc_RoyaltyMinimumPaymentsYearThree

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of royalty minimum payments second year.
+ References
No definition available.
+ Details

Name: nmtc_RoyaltyMinimumPaymentsYearTwo

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of lessor's operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981
+ Details

Name: us-gaap_LessorOperatingLeaseDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981
+ Details

Name: us-gaap_LessorOperatingLeaseTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Details Textual)
6 Months Ended

Mar. 31, 2020

USD ($)

Agreements

Summary of Significant Accounting Policies (Textual)

Deposits in excess of federally insured amounts | $ $ 497,244

Number of licencing agreements | Agreements 2

Equipment [Member] | Minimum [Member]

Summary of Significant Accounting Policies (Textual)

Estimated useful life 3 years

Equipment [Member] | Maximum [Member]

Summary of Significant Accounting Policies (Textual)

Estimated useful life 7 years

Software [Member]

Summary of Significant Accounting Policies (Textual)

Estimated useful life 3 years

X

- Definition
Deposits in excess of federally insured amounts.
+ References
No definition available.
+ Details

Name: nmtc_DepositsInExcessOfFederallyInsuredAmounts

Namespace Prefix: nmtc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of agreements.
+ References
No definition available.
+ Details

Name: nmtc_NumberOfLicencingAgreements

Namespace Prefix: nmtc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: nmtc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Commitments and Contingencies (Details 2)	Mar. 31, 2020 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020 (period from April 1, 2020 to September 30, 2020)	$ 38,462
2021	77,884
2022	79,832
2023	81,827
2024	83,873
2025	42,454
Total lease payments	404,332
Less imputed interest	(65,175)
Total	339,157
Short-term portion	(54,922)
Long-term portion	$ 284,235

Summary of Significant Accounting Policies (Details 4) - shares	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	8,389,987	6,448,613
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	1,355,512	600,209
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	59,090
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	1,648,287

Going Concern (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Going Concern (Textual)
Accumulated deficit	$ 23,221,579	$ 17,238,871

Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Short-term Debt [Line Items]
Accrued interest	$ 152,036
Fair value adjustments	1,683,840
Total	4,921,076
Paulson convertible notes, principal [Member]
Short-term Debt [Line Items]
Total	$ 3,085,200

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities
Net loss	$ (5,982,708)	$ (3,564,714)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	20,965	10,622
Stock-based compensation	1,119,458	189,197
Non-cash interest on convertible notes	1,831,940	51,333
Non-cash discount amortization on convertible notes		233,224
Revaluation of convertible notes	93,858
Revaluation of premium conversion derivatives and warrant liability		129,763
Issuance costs attributed to financing activities	865,567
Loss on notes extinguishment		553,447
Lease liability principal payment deferral	4,038
Right-of-use asset depreciation adjustment	(4,038)
Change in assets and liabilities:
Prepaid and other assets	(40,303)	(74,574)
Accounts payable and other accrued liabilities	(383,855)	(104,578)
Net cash used in operating activities	(2,475,078)	(2,576,280)
Investing activities
Purchase of fixed assets and intangible assets	(40,224)	(65,000)
Net cash used in investing activities	(40,224)	(65,000)
Financing activities
Proceeds from issuance of convertible promissory notes	3,234,800
Issuance costs related to convertible notes	(417,176)
Proceeds from unsecured loans		245,000
Proceeds from issuance of common stock in connection with private placements	255,000	3,768,032
Proceeds from issuance of warrants in connection with private placements		1,416,915
Exercise of warrants		416,333
Exercise of stock options	1,488	3,273
Repayment of unsecured loans		(299,000)
Issuance costs related to private placements	(72,315)	(617,134)
Net cash provided by financing activities	3,001,797	4,933,419
Net increase in cash	486,495	2,292,139
Cash at beginning of period	260,749	13,260
Cash at end of period	747,244	2,305,399
Supplemental non-cash financing and investing transactions:
Conversion of convertible promissory notes to equity		1,678,361
Exercise of premium conversion derivative liability		419,590
Reclassification of warrant liability to equity		835,723
Unpaid issuance costs attributed to convertible notes and private placement	28,756	230,959
Broker warrants issued in connection with convertible notes	419,635
Purchased fixed assets in accounts payable and accrued expenses	2,500
Operating lease right of use asset obtained in exchange for operating lease	$ 335,119

Condensed Balance Sheets - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Current assets:
Cash	$ 747,244	$ 260,749
Prepaid and other assets	81,305	41,002
Total current assets	828,549	301,751
Right-of-use asset	308,055
Intangible assets, net	167,680	178,838
Property and equipment, net	84,943	52,026
Total assets	1,389,227	532,615
Current liabilities:
Accounts payable	1,077,225	1,152,472
Accrued expenses	291,874	617,721
Convertible promissory notes (Note 7)	4,921,076
Total current liabilities	6,290,175	1,770,193
Lease liability	284,235
Total liabilities	6,574,410	1,770,193
Commitments and contingencies (Note 4)
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2020 and September 30, 2019; no shares issued or outstanding as of March 31, 2020 and September 30, 2019.
Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and September 30, 2019; 14,022,423 and 13,493,705 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively.	14,023	13,494
Additional paid-in capital	18,022,373	15,987,799
Accumulated deficit	(23,221,579)	(17,238,871)
Total stockholders' deficit	(5,185,183)	(1,237,578)
Total liabilities and stockholders' deficit	$ 1,389,227	$ 532,615

Stock-Based Compensation (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
Stock-Based Compensation (Details Textual) - USD ($)	Feb. 29, 2020	Oct. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Sep. 30, 2019	Feb. 28, 2018
Restricted Stock [Member]
Stock-Based Compensation (Textual)
Stock options vested			122,767	0	133,272	0
Compensation expense associated with restricted common stock			$ 289,394	$ 0	$ 314,395	$ 0
Number of options, granted			167,851	0	167,851	0
RSUs forfeited shares			0	0	7,003	0
General and Administrative Expense [Member]
Stock-Based Compensation (Textual)
Compensation expense related to the stock awards				$ 23,563		$ 27,543
2017 Equity Incentive Plan [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share			$ 1.15	$ 1.11	$ 1.06	$ 1.12
Compensation expense related to the stock awards			$ 88,806	$ 46,654	$ 526,888	$ 46,654
Stock options vested			46,865	39,675	422,694	39,675
Number of options, granted			20,000	150,548	820,000	325,548
Unrecognized share-based expense is expected to be recognized over a weighted average period					2 years 10 months 25 days
Number of options, forfeited			260,306	0	267,803	0
Total number of stock options outstanding			1,355,512		1,355,512		845,840
Stock-Based Awards [Member]
Stock-Based Compensation (Textual)
Reserved shares of common stock for issuance								250,000
Compensation expense related to the stock awards			$ 153,581		$ 278,175
Stock options vested		60,000			0	50,000
Stock-based services expense				$ 0		$ 115,000
Common stock related to the award liability includes stock options					$ 2.30
Stock-Based Awards [Member] \| Minimum [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share		$ 2.00
Stock-Based Awards [Member] \| Maximum [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share		$ 2.65
Stock-Based Awards [Member] \| Consultant [Member]
Stock-Based Compensation (Textual)
Shares of common stock	90,000	115,000
Stock-Based Awards [Member] \| Consultant One [Member]
Stock-Based Compensation (Textual)
Shares of common stock	36,000	90,000
Stock Option [Member] \| 2016 and 2017 Equity Incentive Plans [Member]
Stock-Based Compensation (Textual)
Unrecognized stock-based compensation			$ 800,000		$ 800,000
Shares available for future grant issuance			2,063,506		2,063,506

Convertible Promissory Notes and Warrant Agreements (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 03, 2019	Feb. 28, 2019	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Nov. 01, 2019
Convertible Promissory Notes and Warrant Agreements (Textual)
Net valuation change of instruments measured at fair value			$ 31,716	$ (116,809)	$ (93,858)	$ (129,763)
Paulson Private Placement [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Issuance cost					419,635
Issuance cost include cash commission					388,176
Legal and third party fee					$ 57,756
Paulson Private Placement [Member] \| Common Stock [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Warrants exercise price			$ 1.87		$ 1.87
Warrants to purchase of common stock shares					259,476
Exercise price, per share			$ 1.87		$ 1.87
Issuance cost					$ 865,567
2017 Convertible Notes [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Convertible notes bear interest at fixed rate			8.00%		8.00%
Principal amount			$ 1,540,000		$ 1,540,000
Convertible notes conversion price per common share			$ 3.00		$ 3.00
Convertible promissory notes converted into common stock		839,179
Shares of common stock issuable upon exercise of warrants		839,179
Issued new warrants exercisable common stock		839,179
Warrant exercise term		4 years 9 months 18 days
Interest on principal amount						30,800
Interest related to amortization of discounts related to bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amount						233,223
Fair value changes related to underlying premium conversion derivative and warrant liability amounted to benefit						6,265
Fair value changes related to underlying premium conversion derivative and warrant liability amounted to expense						6,689
Paulson Convertible Note Offering [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Convertible notes bear interest at fixed rate							13.00%
Principal amount	$ 3,234,800
Gross proceeds of equity qualified financing					$ 3,000,000
Equity qualified financing, description					(i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the 2019 Qualified Financing or (B) the ten day VWAP of the common stock prior to the first closing of a 2019 Qualified Financing. If a change of control transaction occurs prior to a 2019 Qualified Financing or the maturity date, the 2019 Paulson Notes would become payable on demand as of the closing date of such transaction
Description of maximum voting power of surviving entity					Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.
Warrants exercise price			$ 1.87		$ 1.87
Warrants exercisable date of issuance and expire					Nov. 01, 2022
Convertible notes to interest expense					$ 1,831,940
Warrant issuance in connection with execution note agreement	864,913				60,847
Maturity date					May 01, 2020
Interest on principal amount			$ 100,269	100,269	$ 154,144	154,144
Net valuation change of instruments measured at fair value			(31,716)	(31,716)	(31,716)	(31,716)
Net valuation of instruments measured at fair value			$ 93,858	$ 93,858	$ 93,858	$ 93,858
Warrants, description					(i) 0.5 multiplied by (ii) the principal amount of such subscriber’s 2020 Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87.

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Sep. 30, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	14,022,423	13,493,705
Common stock, shares outstanding	14,022,423	13,493,705

Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Mar. 31, 2020 USD ($) Agreements
Summary of Significant Accounting Policies (Textual)
Deposits in excess of federally insured amounts \| $	$ 497,244
Number of licencing agreements \| Agreements	2
Equipment [Member] \| Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	3 years
Equipment [Member] \| Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	7 years
Software [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	3 years